# Peer

# Proteomic profiling of oleamide-mediated polarization in a primary human monocyte-derived tumor-associated macrophages (TAMs) model: a functional analysis

Prapakorn Wisitpongpun<sup>1,\*</sup>, Watunyoo Buakaew<sup>1,2,\*</sup>, Sutatip Pongcharoen<sup>3</sup>, Napaporn Apiratmateekul<sup>4</sup>, Pachuen Potup<sup>1</sup>, Krai Daowtak<sup>1</sup>, Sucheewin Krobthong<sup>5,6</sup>, Yodying Yingchutrakul<sup>6</sup>, Paul J. Brindley<sup>7</sup> and Kanchana Usuwanthim<sup>1</sup>

<sup>1</sup> Cellular and Molecular Immunology Research Unit (CMIRU), Faculty of Allied Health Sciences, Naresuan University, Mueang, Phitsanulok, Thailand

- <sup>2</sup> Department of Microbiology, Faculty of Medicine, Srinakharinwirot University, Bangkok, Thailand
- <sup>3</sup> Division of Immunology, Department of Medicine, Faculty of Medicine, Naresuan University, Mueang, Phitsanulok, Thailand
- <sup>4</sup> Reference Material and Medical Laboratory Innovation Research Unit, Faculty of Allied Health Sciences, Naresuan University, Mueang, Phitsanulok, Thailand
- <sup>5</sup> Center of Excellence in Natural Products Chemistry (CENP), Department of Chemistry Faculty of Science, Chulalongkorn University, Bangkok, Thailand
- <sup>6</sup>National Center for Genetic Engineering and Biotechnology, NSTDA, Pathum Thani, Thailand
- <sup>7</sup> Department of Microbiology, Immunology and Tropical Medicine, and Research Center for Neglected Diseases of Poverty, School of Medicine & Health Sciences, George Washington University, District of Columbia, WA, United States of America
- District of Columbia, WA, Officer States of Americ
- These authors contributed equally to this work.

### ABSTRACT

**Background**. Tumor-associated macrophages (TAMs) play a critical function in the development of tumors and are associated with protumor M2 phenotypes. Shifting TAMs towards antitumor M1 phenotypes holds promise for tumor immunotherapy. Oleamide, a primary fatty acid amide, has emerged as a potent anticancer and immunomodulatory compound. However, the regulatory effects of oleamide on TAM phenotypes remain unclear.

**Methods**. We used real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) and enzyme-linked immunosorbent assay (ELISA) techniques to study the influence of oleamide on primary human monocyte-derived TAM phenotypes, and we investigated the protein expression profiles based on mass spectrometry to analyze the effect of oleamide on macrophage polarization. Moreover, the advantageous binding scores between oleamide and these target candidate proteins are examined using molecular docking.

**Results.** Our study revealed that oleamide effectively suppressed the M2-like TAM phenotype by reducing interleukin (IL)-10 production and downregulating M2-like markers, including vascular endothelial growth factor A (VEGFA), MYC protooncogene, bHLH transcription factor (c-Myc), and mannose receptor C-type 1 (CD206). Moreover, the conditioned medium derived from oleamide-treated TAMs

Submitted 13 March 2024 Accepted 22 August 2024 Published 18 September 2024

Corresponding author Kanchana Usuwanthim, kanchanau@nu.ac.th

Academic editor Xin Zhang

Additional Information and Declarations can be found on page 30

DOI 10.7717/peerj.18090

Copyright 2024 Wisitpongpun et al.

Distributed under Creative Commons CC-BY-NC 4.0

OPEN ACCESS

induces apoptosis of MDA-MB-231 breast cancer cells. Proteomic analysis identified 20 candidate up- and down-regulation proteins targeted by oleamide, showing modulation activity associated with the promotion of the M1-like phenotype. Furthermore, molecular docking demonstrated favorable binding scores between oleamide and these candidate proteins. Collectively, our findings suggest that oleamide exerts a potent antitumor effect by promoting the antitumor M1-like TAM phenotype. These novel insights provide valuable resources for further investigations into oleamide and macrophage polarization which inhibit the progression of breast cancer, which may provide insight into immunotherapeutic approaches for cancer.

Subjects Bioinformatics, Molecular Biology, ImmunologyKeywords Proteomic, Tumor-associated macrophages, Oleamide, Molecular docking

### **INTRODUCTION**

Macrophages are innate immune cells originating from blood monocytes that leave the circulation to differentiate in different tissues, where they contribute to both homeostasis and disease (*Gordon & Plüddemann, 2017*). Tumor-associated macrophages (TAMs) are one of the main tumor-infiltrating immune cell types present in the tumor microenvironment (TME) (*Pan et al., 2020; Zhou et al., 2020*). TAMs play a crucial role in producing immunosuppressive mediators, growth factors, cytokines and chemokines (*Pan et al., 2020; Zhou et al., 2020*).

TAMs also influence tumor growth, angiogenesis, and metastasis (Pan et al., 2020; Zhou et al., 2020). TAMs are the major component of immune cell infiltration in the TME and can constitute up to 50% of the tumor mass (Pan et al., 2020; Zhou et al., 2020). Two major directions of polarized TAMs include classically activated M1 (main markers-major histocompatibility complex DR (HLA-DR), cluster of differentiation (CD) 80/86, inducible nitric oxide synthase (iNOS), C-X-C motif chemokine ligand 10 (CXCL10)) and alternatively activated M2 (main markers-CD206, CD163, CD204, stabilin-1) phenotypes (Pan et al., 2020; Zhou et al., 2020). TAMs exhibit phenotypic plasticity, characterized by the ability to differentiate into functionally distinct subsets in response to specific environmental cues. This process is termed polarization (Mantovani et al., 2004). Polarization of TAMs toward M1/M2-like phenotypes can be manipulated by biomolecules that derive from the TME and cancer cells (Pan et al., 2020; Zhou et al., 2020). At the early stages of tumor formation, macrophages within the TME predominantly express pro-inflammatory M1-like TAMs, whereas tumor progression is associated with increased infiltration of anti-inflammatory M2-like TAMs (Pan et al., 2020; Zhou et al., 2020). Usually, TAMs display a tumor-promoting M2-like phenotype rather than the antitumor M1 phenotype (Lv et al., 2022; Oshi et al., 2020; Zhang et al., 2014). The M1/M2 ratio is considered a crucial prognostic marker of cancer disease. A high M1/M2 ratio appears to be correlated with favorable outcomes, whereas a low M1/M2 TAM ratio frequently implies tumor development and a poor prognosis (Lv et al., 2022; Oshi et al., 2020; Zhang et al., 2014). Therefore, finding a molecule that can target TAMs toward

M1-like phenotypes and/or suppress M2-like phenotypes has become a novel strategy for treatment of solid tumors.

Oleamide is a fatty amide derived from oleic acid and serves as a lipid-signaling molecule (Fowler, 2004). Oleamide was first recognized as a sleep-inducing substance and later found to have wide-ranging effects on the central nervous system (CNS) by interacting with various neurotransmitter receptors such as gamma-aminobutyric acid (GABA), serotonin and dopamine acetylcholine (Boger, Henriksen & Cravatt, 1998; Maya-López et al., 2020; Mendelson & Basile, 2001; Verdon et al., 2000). In plant extracts, oleamide compounds purified from green algae Codium fragile suppressed lipopolysaccharide (LPS)-induced tumor necrotic factor-alpha (TNF- $\alpha$ ), IL-1  $\beta$ , and IL-6 secretion in RAW254.7 cells by inhibiting the phosphorylation of the inhibitor of kappa B (I  $\kappa$  B)-  $\alpha$  (Moon et al., 2018). Oleamide was also identified in extracts of the leaf of Moringa oleifera that exert anticancer effects by inducing cell apoptosis and cell-cycle arrest of MDA-MB-231 breast cancer cell line (Wisitpongpun et al., 2020). In microglia cells, a population of macrophages found in the CNS, oleamide exerts a dual activity with induction of phagocytosis and suppression of LPS-induced inflammation (Ano et al., 2015). Moreover, induced the polarization of naïve macrophages toward M1 macrophages by regulating the NLRP3-inflammasome pathway in primary human monocyte-derived macrophages (MDMs) (Wisitpongpun, Potup & Usuwanthim, 2022). The inflammasome is a cytosolic multiprotein complex that assembles in response to various stimuli, including infection and stress responses (De Zoete et al., 2014). These complexes consist of upstream nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) and the downstream effector caspase-1. Inflammasome activation leads to the production of key pro-inflammatory cytokines, IL-1  $\beta$  and IL-18, as well as gasdermin D, which triggers pyroptosis, a form of programmed cell death (Swanson, Deng & Ting, 2019). NLRP3, a NOD-like receptor containing leucine-rich repeats (LRRs) and a pyrin domain, is one of the inflammasome sensors that recognizes a broad range of stimuli. Although oleamide exerts potent anticancer and immunomodulatory activity, its effect on human TAM polarization influencing cancer cells have yet to be investigated.

Here, we investigated the immunoregulatory effect of oleamide on TAM phenotypes using primary human monocytes as a model. TAM phenotypes were characterized using a combination of ELISA, qRT-PCR, and apoptosis analysis. We employed highthroughput proteomics to identify and quantify the proteins in oleamide-treated TAMs, and additionally, selected key proteins were subjected to molecular docking analysis to further elucidate their interaction with oleamide.

### **MATERIALS & METHODS**

#### **Cell culture**

Primary human monocytes were collected from a blood buffy coat obtained from healthy donors at the Blood Bank of Naresuan University Hospital. This research protocol was ethically approved by the Naresuan University institutional review board (approval number 0172/62; approval date, May 28, 2019). This study adhered to ethical guidelines by obtaining verbal consent from all blood donors. To ensure the complete protection of participant

privacy, the manuscript and associated supplemental files are devoid of any personally identifiable information. The isolated cells were cultured in the Roswell Park Memorial Institute (RPMI) 1640 (Gibco, Carlsbad, CA, USA) supplemented with 10% single donor human serum and 1% penicillin/streptomycin (Gibco). MDA-MB-231 cells, acquired from the American Type Cell Collection (ATCC) (Manassas, VA, USA), were cultured in Dulbecco's Modified Eagle's Medium (DMEM) (Gibco) supplemented with 10% fetal bovine serum (FBS) (Gibco) and 1% penicillin/streptomycin (Gibco). Maintenance of all cell cultures was conducted at 37 °C in a humidified environment with 5% CO<sub>2</sub>.

### Harvesting of tumor-conditioned medium

To procure tumor-conditioned media, MDA-MB-231 cells were cultivated at a density of  $2 \times 10^5$  cells in a T-75 flask until attaining 80% confluency in complete medium. Subsequently, the medium was substituted with 0.2% FBS medium for a duration of 24 h. Following the incubation period, the resulting tumor-conditioned medium was harvested and subjected to centrifugation at 3,000 rpm for 5 min to eliminate suspended cells. The resultant supernatant was then collected, and 10% single donor human serum was supplemented to restore the medium.

### Isolation of primary human monocytes

Following the protocol outlined by Menck et al. (2014) cells isolated from the blood buffy coat of healthy donors underwent a systematic procedure. Initially, the buffy coat was partitioned into two 50 ml tubes and centrifuged at 3,000 rpm for 30 min. The obtained serum was utilized for the preparation of single donor human serum, while the white blood cell (WBC) layer was transferred to a separate tube and suspended in phosphate-buffered saline- ethylenediaminetetraacetic acid (PBS-EDTA) (1 mM) to achieve a volume of 20 ml. The diluted WBCs were gently overlaid onto Ficoll-Paque solution (density 1.077 g/ml, GE Healthcare, Chicago, IL, USA) in a 1:1 ratio and centrifuged at 3,000 rpm for 30 min. Subsequently, the peripheral blood mononuclear cells (PBMCs) layer at the interface was transferred to a fresh 50 ml tube and washed once with 40 ml PBS-EDTA. Upon removal of the supernatant, the PBMC pellet was resuspended in 15 ml of PBS-EDTA. Diluted PBMCs were carefully overlaid onto 46% Percoll solution (density 1.131 g/ml; GE Healthcare) in a 1:1 ratio and centrifuged at 3,000 rpm for 30 min. The resulting monocyte layer at the interface was then transferred to a new 50 ml tube and washed 3-5 times with 40 ml PBS-EDTA to eliminate residual platelets. Subsequently, the monocytes were cultured in RPMI 1640 supplemented with 10% human serum and 1% penicillin/streptomycin for 6 days to differentiate into MDMs. The purity of MDMs from days 0-6 is illustrated in Fig. S1.

### Heat-inactivated of single donor human serum

Following the protocol for human serum collection, blood buffy coats from healthy donors were processed. Initially, the buffy coat was divided between two 50 ml tubes and subjected to centrifugation at 3,000 rpm for 30 min. Subsequently, serum was transferred to a fresh 50 ml tube and incubated at 56 °C in a water bath for 30 min to inactivate the complement. Following this, the serum underwent centrifugation at 3,000 rpm for 15 min to eliminate

residual fibrin and platelets. The supernatants obtained were then transferred to 15 ml tubes and stored at -20 °C until required for further use.

### Tumor-associated macrophages (TAMs)

Tumor-associated macrophages (TAMs) were generated following the protocol outlined by previous study (*Prapakorn Wisitpongpun, 2022*). MDMs were co-cultured with MDA-MB-231 breast cancer cells within a Transwell co-culture system (0.4  $\mu$ m pore size polycarbonate; SPL Life Sciences, Pocheon, Korea). MDA-MB-231 cells (6 × 10<sup>3</sup> cells/well) were seeded in the upper chamber of the Transwell plate and incubated overnight in complete DMEM prior to co-culture. Freshly isolated human monocytes (1 × 10<sup>5</sup> cells/well) were seeded to the lower chamber, and divided into four experimental groups: (1) complete medium (non-co-culture), (2) complete medium (co-culture negative control), (3) complete medium supplemented with IL-4 (50 ng/ml), IL-10 (50 ng/ml), and macrophage colony-stimulating factor (M-CSF) (50 ng/ml), and (4) a 1:1 mixture of complete medium and tumor-conditioned medium, further supplemented with IL-10 (50 ng/ml) and M-CSF (50 ng/ml). The upper chamber containing MDA-MB-231 cells was then inserted into the Transwell plate (except for the non-co-culture group), and cells were maintained for six days. The conditioned medium was replaced every three days, and cell harvesting was performed on the sixth day.

### Reverse transcription-quantitative real-time PCR (RT-qPCR)

Cell pellets were harvested from untreated macrophages (control), untreated TAMs, and oleamide-treated TAMs, constituting the three experimental groups (n = 3 per group). These pellets were subsequently utilized for total RNA extraction procedures. Total RNA was isolated utilizing Trizol reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's protocol, with no additional DNase treatment. The purity of the total RNA extract was assessed spectrophotometrically using a Nanodrop instrument. Subsequently, cDNA synthesis was performed using the Tetro cDNA Synthesis Kit (Bioline, Memphis, TN, USA). Briefly, 5  $\mu$ g of total RNA was mix with mastermix (Tetro reverse transcriptase 200 U, oligo (dT)<sub>18</sub> primer mix, 10mM dNTP mix, and RiboSafe RNase inhibitor). The mixture was subjected to an initial incubation period at 45 °C for 30 min. This was followed by a termination step at 85 °C for 5 min, and the reaction was subsequently halted *via* rapid cooling on ice. The resulting cDNAs (100 ng/reaction) were subjected to amplification with various primers (referenced in Table S1) employing the SensiFAST<sup>™</sup> SYBR<sup>®</sup> No-ROX Kit (Bioline). The PCR protocol involved polymerase activation at 95 °C for 2 min, followed by 40 cycles consisting of a denaturation step at 95 °C for 5 s, annealing and extension at 60 °C for 1 min, and a final extension at 72 °C for 5 min. To evaluate gene expression levels, a relative gene expression approach was employed. Briefly, the cycle threshold (Ct)-value of the target gene was compared to that of untreated control cells (MØcontrol) to determine the relative expression of the target genes. Relative differences in gene expression among groups were calculated from the quantification Ct values, initially normalized to the  $\beta$ -actin housekeeping gene in the same sample ( $\Delta$ Ct), and then expressed as fold-change over control  $(2^{-\Delta\Delta Ct})$ . Real-time fluorescence detection was performed using a CFX96

Touch Real-Time PCR Detection System (Bio-Rad, Hercules, CA, USA). Analysis of Ct data was carried out employing the CFX Manager software (version 3.1), following established quantitative real-time PCR analysis protocols.

### **Apoptosis analysis**

Cellular apoptosis was examined using a Muse Cell Analyzer (EMD Millipore, St. Louis, MO). MDA-MB-231 cells were cultured in 24-well plates at a density of  $5 \times 10^4$  cells/well. The cells were treated with conditioned media from various conditions, including untreated-TAMs (TAMs), oleamide-treated TAMs (TAMs + OLA), M0 macrophages (MØCtr), complete medium alone (control), or complete medium supplemented with 20 µg/ml oleamide (OLA only) for 24 h at 37 °C with 5% CO<sub>2</sub>. Following treatment, cells were collected into microcentrifuge tubes, resuspend with 5% FBS in complete medium up to the final volume of 100 µl, and stained with 100 of µl Muse<sup>TM</sup> Annexin V and Dead Cell reagent (cat. no. MCH100105; EMD Millipore). Cells were incubated for 20 min at room temperature in dark. Finally, stained cells were then analyzed within 10 min.

### Enzyme-linked immunosorbent (ELISA) assay

For the determination of cytokine levels, a sandwich enzyme-linked immunosorbent assay (ELISA) kit (Sino Biological Inc., Beijing, China) was utilized to measure TNF- $\alpha$ , IL-6, IL-1 $\beta$ , and IL-10 cytokines. The absorbance of the reaction was quantified at 450 nm using an EnSpire<sup>(R)</sup> Multimode microplate reader (PerkinElmer).

### Cell viability assay

To assess cell viability, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was employed, wherein cells were seeded at a density of  $1 \times 10^4$  cells/well in a 96-well plate containing 100 µl of complete medium. Subsequently, cells were exposed to various treatments, including untreated-TAMs (TAMs), oleamide-treated TAMs (TAMs + OLA), M0 macrophages (MØCtr), complete medium alone (control), or complete medium supplemented with 20 µg/ml oleamide (OLA only) for 24, 48, and 72 h. Additionally, to evaluate the cytotoxicity of oleamide, cells were exposed to serial concentrations of oleamide ranging from 0–240 µg/ml for 24 h. Following treatments, cells were washed with PBS and incubated with MTT salt solution for 3 h at 37 °C. The resulting formazan crystals were dissolved in 100 µl of dimethyl sulfoxide (DMSO), and absorbance was measured at 570 nm using a microplate reader.

### Protein extraction and digestion for label-free proteomic analysis

This study collected whole cell lysates from three experimental groups: macrophage control, TAMs, and TAMs+OLA, from two different blood donors (AB and O) for proteomic analysis. The sample preparation was prepared using previously protocol with minor modifications (*Krobthong et al., 2022*). Briefly, the protein solution was concentrated using a 3 kDa molecular weight cut-off membrane and then precipitated with ice-cold acetone (1:5 v/v). Following precipitation, the protein pellet was dissolved in a solution containing 0.3% RapidGest SF (Waters Corp., Milford, MA) and 2.5 mM ammonium bicarbonate (Sigma Aldrich Co.). To facilitate trypsin digestion, 30  $\mu$ g of total protein

was used. Sulfhydryl bond reduction was achieved by treating the protein solution with 1 mM tris(2-carboxyethyl) phosphine hydrochloride (TECP) (Sigma Aldrich) in 2.5 mM ammonium bicarbonate at 37 °C for 2 h, followed by sulfhydryl alkylation with 5 mM indole-3-acetic acid (IAA) (Sigma Aldrich) in 2.5 mM ammonium bicarbonate at room temperature for 50 min in the dark. The solution was then purified using a Zeba Spin Desalting Column (Thermo Fisher Scientific, Waltham, MA, USA). The resulting flow-through solution was enzymatically digested using trypsin (Promega Co., Madison, WI, USA) at a ratio of 1:40 (enzyme to protein) and incubated at 37 °C for 6 h. The digested solution was prepared for liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis after being dried and reconstituted in 0.1% formic acid.

# LC-MS/MS setting and data processing for label-free proteomic analysis

LC-MS/MS spectral data were acquired in positive mode using an HF-X hybrid Quadrupole-Orbitrap<sup>™</sup> Mass Spectrometer coupled with an EASY-nLC1000 nano-LC system equipped with a nano C18 column (Thermo Fisher Scientific). The protein amount that loaded onto column was 1,000 ng (2 uL of 500 ng/uL). The mobile phase compositions were as follows: mobile phase A, 0.1% formic acid in water, and mobile phase B, 90% acetonitrile with 0.1% formic acid. LC separation was carried out utilizing a linear gradient of 3% to 60% mobile phase B over 135 min at a constant flow rate of 300 nL/min. After being cleaned with 90% mobile phase B for 10 min, the analytical column was regenerated by being re-equilibrated with 3% mobile phase B for 35 min. The peptides were subjected to data-dependent acquisition (TopN15 method) followed by higher-energy collisional dissociation with a collision energy of 29 eV. Full scan mass spectra were recorded in the m/z range of 350 to 1,200, with an automatic gain control (AGC) target of  $3e^6$  ions and a resolution of 120 k. MS/MS scanning was started when the AGC target reached 5e<sup>4</sup> ions, and a resolution of 15k was used. The acquired raw mass spectra (.raw file) were processed using Proteome Discoverer<sup>™</sup> 2.4 software (Thermo Fisher Scientific) and matched against the UniProt protein database (https://www.uniprot.org/; organism: Homo sapiens; accessed on 14 January 2023) for identification. For protein identification and quantification, the following parameters were used: MS tolerance, 20 ppm; MS/MS tolerance, 0.05 Da; digestion enzyme, trypsin; fixed modification, cysteine carbamidomethylation; and variable modification, methionine oxidation. To ensure robust identification, the false discovery rate (FDR) for peptides and proteins was set at 1%. For normalization and relative abundance determination, protein intensity was normalized to the total peptide amount for each LC run using the normalization algorithm (total intensity count) of the software (Griss et al., 2020).

### Gene Ontology annotation and protein-protein interaction network

The Gene Ontology (GO) is a structured and standardized information source representing biological knowledge, which is used to define and categorize genes and gene products based on three different aspects, including cellular component, molecular function, and biological process (*Ashburner et al., 2000; The Gene Ontology et al., 2023*). GO cellular component is

classification of characterizing the functions of gene products based on their location within cellular structures. GO molecular function aspects describe the specific biochemical activities of gene products at the molecular level, including catalysis and transport. Notably, these aspects do not provide information regarding the context or temporal specificity of these activities. On the other hand, GO biological processes are defined as a series of molecular events that lead to the completion of a specific cellular process, but are not necessarily equivalent to a specific pathway. Examples of biological processes include DNA repair and signal transduction. Protein–protein interaction (PPI) network analysis was conducted using a method that involved searching for differentially expressed proteins (DEPs) in the STRING database version 11. The resulting interaction network was visualized with a high confidence score ( $\geq 0.7$ ). To analyze the GO annotation and PPI, Cytoscape software version 3.9.1 was employed, with the stringApp add-on application utilized for this study.

# Integration of functional enrichment analysis and KEGG pathways database

To conduct functional enrichment analysis, a list of significant differentially expressed proteins that were commonly found in both donor AB and O was selected. The interactive and collaborative HTML5 gene list enrichment analysis tool, Enrichr (https://maayanlab.cloud/Enrichr) (*Chen et al., 2013; Kuleshov et al., 2016; Xie et al., 2021*), was utilized to integrate information regarding GO biological processes and protein pathways based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) 2021 human library (*Kanehisa, 2019; Kanehisa et al., 2023; Kanehisa & Goto, 2000*). Firstly, the list of Uniprot IDs protein in donor AB and O was converted to Gene IDs using the Uniprot Retrieve/ID mapping tool (https://www.uniprot.org/id-mapping). Subsequently, the resulting list of gene identifications (IDs) was submitted to Enrichr. To visualize the interaction network of GO biological process, KEGG pathway, and overlapped genes, Enrichr-KG (https://maayanlab.cloud/enrichr-kg) was employed with the following criteria: minimum libraries per gene = 1, minimum links per gene = 1, minimum links per term = 1.

# Identification of the differentially expressed genes using Gene Set Enrichment Analysis

To further elucidate the differential gene expression in both TAMs and oleamide-treated TAMs, we conducted a Gene Set Enrichment Analysis (GSEA) using version 4.3.2 of the GSEA desktop application (*Mootha et al., 2003; Subramanian et al., 2005*). The list of Uniprot IDs was uploaded corresponding to the expressed proteins and aligned them with the Human\_UniProt\_IDs\_MSigDB.v2023.1. Hs chip platform. Subsequently, we categorized the data into two distinct phenotypic groups: TAMs (TAMs) and TAMs treated with oleamide (OLA), each consisting of three samples. For this analysis, we employed the Molecular Signatures Database (MSD) collection of curated gene set (c2.all.v2023.1.Hs.symbols.gmt), which contained seven gene subsets; chemical and genetic perturbations (CGP), canonical pathways (CP), BioCarta subset of CP, KEGG subset of CP, pathway interaction database (PID) subset of CP, Reactome subset of CP,

and WikiPathways subset of CP (*Liberzon et al., 2015*; *Liberzon et al., 2011*). Our analysis was conducted using the following parameters: 1,000 permutations, gene set sizes ranging from 15 to 500, a *p*-value cutoff of 0.05, and FDR correction. The other parameters were maintained default, including enrichment statistics (weighted), gene list ranking method (Signal2Noise), gene list sorting mode (real), randomization mode (no balance), collapsing mode for probe sets (max probe), and normalization mode (meandiv).

### **Molecular docking**

To observe the potential interaction of oleamide on target molecule, protein structures that were significantly up- and down-regulated and known to be involved in macrophage function were retrieved from the Protein Data Bank (PDB) (https://www.rcsb.org/) and saved in the "PDB" format as protein receptors. These protein receptors were prepared for docking by removing all non-standard residues and water molecules, assigning charges, and modifying incomplete amino acid side chains using the Dock Prep tool (Shapovalov Maxim & Dunbrack Roland Jr, 2011) on UCSF Chimera alpha version 1.17 (Pettersen et al., 2004). The 3D structure of oleamide was retrieved from the PubChem database (https://pubchem.ncbi.nlm.nih.gov/) (PubChem CID 5283387) and optimized using the Dock Prep tool on UCSF Chimera alpha similar to the protein receptors. The molecular docking analysis was performed using AutoDock Vina software version 1.2.3 (Eberhardt et al., 2021; Trott & Olson, 2010) to assess the binding score of protein-ligand complexes. An affinity value of <-5 kcal/mol indicated a good binding interaction between the oleamide and protein targets (Gaillard, 2018). The 2D and 3D structures of the resulting protein-ligand complexes were visualized using Discovery Studio Visualizer 2021 software version 21.1.0.

### Statistical analysis

GraphPad Prism 6.0 software (GraphPad Software Inc., San Diego, CA, USA) was used to perform one-way analysis of variance (ANOVA) with multiple comparison corrections (Dunnett test) for comparisons of more than two groups. All results were presented as mean  $\pm$  standard error of the mean (SEM). Statistics were considered significant for *p*-values <0.05. For proteomic analysis, the changes in protein folding were assessed through pairwise comparisons, and statistical significance was determined using the Benjamini–Hochberg method to adjust *p*-values, employing ANOVA with a backgroundbased calculation approach. The Fisher's exact test was employed to assess the significance of the overlap between the input gene list and the gene sets within each gene set library used for the enrichment scoring method.

### RESULTS

#### Generation of human monocytes-derived TAMs

In exploring the optimal conditions for TAM generation, primary human MDMs were cocultivated with human breast cancer MDA-MB-231 cells utilizing the Transwell co-culture approach. The MDMs were cultured in the lower compartment of the Transwell plate under various conditions, including solely complete medium, complete medium supplemented

#### Transwell co-cultured model



**Figure 1** The protocol for generating human monocyte-derived TAMs in this study. A co-culture system of MDMs and MDA-MB-231 cells was established using Transwell plate. The cells were maintained under standard cell culture conditions (37 °C, 5% CO<sub>2</sub>). MØmedium (representing naïve macrophages or M0), interleukin-4 (IL-4), interleukin-10 (IL-10), macrophage colony-stimulating factor (M-CSF), or tumor-conditioned medium (TCM). The figure was generated using BioRender.com (https://www.biorender.com/).

Full-size DOI: 10.7717/peerj.18090/fig-1

with IL-4, IL-10, and M-CSF, or a mixture of complete medium and tumor-conditioned medium (in a 1:1 ratio) with additional IL-4, IL-10, and M-CSF. Over a span of 6 days, MDMs were co-cultured with MDA-MB-231 cells to drive the differentiation of naïve monocytes into TAMs (as depicted in Fig. 1).

Bright-field microscopy was employed to observe the morphology of co-cultured macrophages on day 6 (Fig. 2A). Across all conditions, macrophages displayed a consistent pattern of alignment by clustering and aligning along the well. While co-cultured macrophages in complete medium only exhibited small, round, elongated shapes, those treated with cytokines or tumor-conditioned medium plus cytokines displayed greater elongation, resembling spindle-like shapes. The phenotypic characterization of TAMs was based on the expression of signature genes associated with M2-like TAM phenotypes, including *c-Myc* (an oncogene with pro-tumor effects), matrix metallopeptidase 9 (*MMP9*) (which mediates extracellular matrix degradation), *VEGFA* (an angiogenesis-inducing growth factor), and *CD206* (a mannose receptor), along with the expression of the M1-like TAM phenotype gene *HLA-DR*, which is typical of antigen-presenting cells (APCs).

Analysis of tumor-associated gene expression revealed that co-culturing MDMs with MDA-MB-231 cells without cytokine stimulation was adequate to induce the expression of VEGFA and MMP-9 genes but did not significantly affect c-Myc gene expression (Fig. 2B). Conversely, co-culturing MDMs in complete medium supplemented with cytokines or in a mixture of complete medium and tumor-conditioned medium with cytokines



**Figure 2** Phenotypical characterization of human monocyte-derived TAMs using Transwell coculture. (A) Cell morphology of monocyte-derived TAMs after 6 days of Transwell co-culture with MDA-MB-231 cells. Morphology was observed under an inverted bright-field microscope at 10X magnification. (B) Gene expression of M1/M2-like TAM phenotypes using RT-qPCR. Total RNAs were extracted from co-cultured macrophages and MØcontrol on day 6. Data represent the mean  $\pm$  SEM of three independent experiments (\*p < 0.05,\*\*p < 0.01,\*\*\*p < 0.001), ns (not significant), TCM (tumor-conditioned medium), c-Myc (pro-tumor oncogene), MMP9 (matrix metallopeptidase 9), VEGFA (vascular endothelial growth factor A), CD206 (mannose receptor), HLA-DR (major histocompatibility complex class II), IL-4 (interleukin-4), IL-10 (interleukin-10), M-CSF (macrophage colony-stimulating factor). Full-size  $\cong$  DOI: 10.7717/peerj.18090/fig-2 significantly upregulated the expression of all TAM genes. Notably, co-culturing MDMs in complete medium with cytokines led to greater expression of c-Myc and MMP-9 compared to the tumor-conditioned medium condition (Fig. 2B). Our data indicate that Transwell co-culture of macrophages and MDA-MB-231 cells with the addition of IL-4, IL-10, and M-CSF provides a more suitable model for *in vitro* generation of M2-like TAMs.

# Oleamide initiated the reprogramming of M2-like TAMs towards M1-like TAM phenotypes

Recent research by Wisitpongpun, Potup & Usuwanthim (2022) highlighted oleamide's immunomodulatory potential in promoting naïve M1 macrophage polarization and inflammasome activation. Building on this, we aimed to investigate oleamide's effect on TAM polarization. On day 6 of co-culture, TAMs were exposed to oleamide  $(20 \,\mu g/ml)$  for 24 h. The TAM phenotypes were evaluated based on the expression of TAM-associated genes (VEGFA, c-Myc, and MMP-9), M1-like TAM genes (iNOS and HLA-DR), and M2-like TAM genes (CD206, IL-10, and CD163). Treatment with oleamide led to a significant reduction in the expression of c-Myc, VEGFA, CD206, and IL-10 genes compared to untreated TAMs, indicating suppression of M2-like TAM differentiation (Fig. 3A). Additionally, oleamide upregulated the expression of HLA-DR and slightly increased iNOS genes, associated with M1-like TAMs (Fig. 3A). Complementing these findings, ELISA analysis revealed increased levels of IL-1  $\beta$  in TAMs treated with oleamide, while TNF- $\alpha$  and IL-6 levels did not significantly differ from untreated TAMs (Fig. 3B). Moreover, decreased IL-10 levels were observed in oleamide-treated TAMs, consistent with the downregulation of IL-10 gene expression. Overall, these results suggest that oleamide treatment diminishes protumor M2-like TAMs while preserving antitumor M1-like TAMs in a Transwell co-culture model with MDA-MB-231 cells.

# The conditioned medium obtained from TAMs treated with oleamide resulted in a reduction of cell viability and initiation of apoptosis in MDA-MB-231 cells

In our study, we observed a shift of protumor M2-like tumor-associated macrophages (TAMs) towards antitumor M1-like TAM phenotypes following treatment with oleamide. This led us to hypothesize that oleamide might exert anti-tumor effects by enhancing the cytotoxicity of M1-like TAMs against tumor cells. To investigate this hypothesis, we collected conditioned media from co-cultured TAMs with or without oleamide and evaluated their anticancer activity on MDA-MB-231 cells over 72 h using the MTT assay. We found that conditioned media from untreated-TAMs promoted cancer cell proliferation at 48 and 72 h, whereas conditioned media from oleamide-treated TAMs significantly suppressed cancer cell proliferation at 24 and 48 h (Fig. 4A). To validate these findings, we treated MDA-MB-231 cells with conditioned media for 24 h and assessed apoptosis. We observed an increase in both early and late apoptotic cells when treated with conditioned media from oleamide-treated TAMs compared to untreated controls (Fig. 4C).

Additionally, we investigated the direct effect of oleamide on cancer cells by treating MDA-MB-231 cells with varying concentrations of oleamide for 24 h in complete medium. Oleamide exhibited a minimal increase in apoptotic cells at lower concentrations, but a



**Figure 3** Effect of oleamide on human TAM polarization. (A) Gene expression by RT-qPCR. (B) Cytokine levels as established using ELISA. Transwell generated TAMs (day 6) were incubated in the presence or absence of oleamide (20 µg/ml) for 24 h. Afterward, total RNA was extracted for analysis of M1/M2-like TAM gene expression. Cell culture supernatants were used to measure pro-and anti-xinflammatory cytokine production. The MØcontrol represented naïve macrophages or M0 macrophages. Data are represented as mean  $\pm$  SEM of three independent experiments (\**p* < 0.05, \*\**p* < 0.01,\*\*\**p* < 0.001), ns (not significant), TAMs (tumor-associated macrophages), OLA (oleamide), c-Myc (pro-tumor oncogene), MMP9 (matrix metallopeptidase 9), VEGFA (vascular endothelial growth factor A), CD206 (mannose receptor). CD163 (hemoglobin-haptoglobin scavenger receptor), iNOS (inducible nitric oxide synthase), HLA-DR (major histocompatibility complex class II), IL-6 (interleukin-6), IL-1  $\beta$  (interleukin-1  $\beta$ ), IL-10 (interleukin-10), TNF- $\alpha$  (tumor necrosis factor-alpha). Full-size  $\cong$  DOI: 10.7717/peerj.18090/fig-3



**Figure 4** Effect of oleamide-treated TAM-conditioned medium on the viability and apoptosis of MDA-MB-231 cells. (A) Viability of MDA-MB-231 cells following exposure to various conditions, including complete medium (NC), oleamide (20  $\mu$ g/ml) in complete medium (OLA only), or conditioned medium obtained from untreated TAMs (TAMs), oleamide-treated TAMs (TAMs + OLA), or M0 macrophages (MØCtr). (B) Viability of MDA-MB-231 cells after exposure to varying concentrations of oleamide for 24 h. (C) Analysis of apoptosis in MDA-MB-231 cells following a 24-hour incubation period. The bar graph illustrates the percentage of cell counts as depicted in (C). The data are presented as the mean  $\pm$  SEM of three independent experiments (\*p < 0.05,\*\*p < 0.01,\*\*\*p < 0.001). TAMs (tumor-associated macrophages), OLA (oleamide), and NC (negative control).

Full-size 🖾 DOI: 10.7717/peerj.18090/fig-4

more pronounced decrease in cell viability was observed at higher concentrations, with complete inhibition of cell viability at 240  $\mu$ g/ml (Fig. 4B). These results suggest that oleamide's anticancer activity may be mediated indirectly through the promotion of M1-like TAM phenotypes, enhancing their cytotoxicity against cancer cells.

### Protein profiling between the TAMs and TAMs co-cultured with OLA

The proteomic analysis revealed 2,473 overlapping proteins identified in both TAMs and TAMs + OLA groups in donor AB, and 1,689 in donor O (Fig. 5). To determine statistical

significance, a FDR of 0.05 was applied, with fold-changes considered significant when  $\geq$  2 and adjusted *p*-value <0.05. Among the significantly altered proteins, there were 90 upregulated proteins in donor AB and 102 upregulated proteins in donor O, while there were 176 downregulated proteins in donor AB and 147 downregulated proteins in donor O. The PPI network analysis and visualization were performed using Cytoscape software version 3.9.1 with stringApp from STRINGDB. A minimum required interaction score of  $\geq$  0.7 was applied to construct the network as shown in Figs. 6 and 7. The GO annotation analysis was performed to identify the most abundant up-and down-regulated proteins in both donors based on their cellular component, biological process, and molecular function. The results indicated that the organelle, protein-containing complex, and cytoplasm were the most affected cellular components. In terms of biological processes, the upregulated proteins were primarily involved in transport, whereas the downregulated proteins were mainly associated with positive regulation of biological processes and regulation of macromolecule metabolic processes. The analysis of molecular function revealed that the top three downregulated protein groups in the OLA treatment were heterocyclic compound binding, catalytic activity, and RNA binding. Table 1 presents the top 10 most up-regulated proteins identified in donor AB and O. Among the most up-regulated proteins in donor AB were Filaggrin, Perilipin-2 (Adipophilin), and Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5, while the top three up-regulated proteins in donor O were haptoglobin (zonulin), Fibroblast growth factor receptor-like 1 (FGF receptor-like protein 1), and cyclin-dependent kinase-like 1. The top 10 most downregulated proteins were presented in Table 2. Among the most down-regulated proteins in donor AB were matrix metalloproteinase-9 (MMP-9), HLA class I histocompatibility antigen, alpha chain F (CDA12), and interleukin-18 (IL-18), while with the donor O these were putative protein-lysine deacylase ABHD14B, protein mono-ADP-ribosyltransferase PARP14, and destrin (actin-depolymerizing factor) (ADF). The datasets generated during and/or analyzed during the current study are available in the Proteomics Identifications Database (PRIDE) repository, https://www.ebi.ac.uk/pride/archive/projects/PXD043461.

# Identification and prediction of target protein responsible for macrophage polarization

To further elucidate the proteins associated with macrophage polarization, a comprehensive analysis was conducted on the proteins overlapping between donor AB and O using Enrichr-KG. The resulting proteins were clustered based on their involvement in GO biological processes, KEGG pathways, and overlapping gene terms, as illustrated in Fig. 8. Among the 21 up-regulated proteins identified, Table 3 presents the top 10 signaling pathways and overlapping genes that exhibited significant associations. These pathways include systemic lupus erythematosus, neutrophil extracellular trap formation, leishmaniasis, complement and coagulation cascades, *Staphylococcus aureus* infection, neomycin, kanamycin and gentamicin biosynthesis, HIF-1 signaling pathway, phagosome, tuberculosis, and nitrogen metabolism. While the 39 down-regulated proteins were identified, Table 4 presents the top 10 signaling pathways and overlapping genes that exhibited significant associations. These pathways include coronavirus disease, ribosome, oxidative phosphorylation, ether lipid





Full-size DOI: 10.7717/peerj.18090/fig-5

metabolism, arachidonic acid metabolism, Fc epsilon RI signaling pathway, Parkinson's disease and prion disease.

# The differential gene set expression in both TAMs and oleamide-treated TAMs

The GSEA analysis showed that oleamide-treated TAMs were positively associated with several gene sets, such as HIF-1 transcription factor (TF) pathway and regulation of insulin-like growth factor (IGF) transport and uptake by insulin-like growth factor binding proteins (IGFBPs), as shown in Fig. 9. The expression levels of several genes (red cells) matched the expression levels of the genes ranked by Enrichr-KG in Table 3. These genes were hexokinase-2 (HK2), H2B clustered histone 21 (H2BC21), complement C3 (C3), and transferrin (TF). This showed the consistency of the outcomes from both tools for over-presentation analysis. The statistic of each gene set is show in Table 5. Other gene





sets, including systemic lupus erythematosus, response to elevated platelet cytosolic ca<sup>2</sup>, transcriptional regulation by small RNAs, gene silencing by RNA, Rho GTPases activate protein kinases N (PKNs), reproduction, and HIF-1 targets and the detail of gene names in each gene set can be found in Files S2–S12.

### Molecular docking analysis of selected proteins

Based on the identification of the top 10 significantly up- and down-regulated terms presented in Tables 3 and 4, candidate proteins were selected based on their functional toward M1-macrophage polarization for further investigation on binding to oleamide. Docking analysis was conducted using oleamide (PubChem CID 5283387) as the ligand, focusing on the candidate up-regulated proteins including hexokinase-2 (*HK2*) (PDB ID: 2NZT), as well as proteins involved in their interaction, such as solute carrier family 2 member 1 (*SLC2A1*) (PDB ID: 5EQG), solute carrier family 2 member 4 (*SLC2A4*) (PDB ID: 7WSM), transferrin receptor protein 1 (*TFRC*) (PDB ID: 6OKD), serine/threonine-protein kinase mTOR (MTOR) (PDB ID: 3FAP) and hypoxia-inducible factor 1-alpha (*HIF1A*) (PDB ID: 1H2K). Additionally, the analysis encompassed the examination of down-regulated proteins, namely prostaglandin E synthase 3 (*PTGES3*) (PDB ID: 1EJF), signal





Full-size DOI: 10.7717/peerj.18090/fig-7

transducer and activator of transcription 2 (*STAT2*) (PDB ID: 6UX2), and nucleosome assembly protein 1 like 1 (*NAP1L1*) (PDB ID: 7UN6). The docking analysis between oleamide and the selected candidate proteins was visualized through 2D and 3D structures, as depicted in Fig. 10. Detailed information regarding the binding affinity was evaluated by assessing parameters such as docking score, the number of hydrogen bonds formed, and the interactions with specific amino acids. A comprehensive summary of these relevant parameters is presented in Table 6.

### DISCUSSION

Tumor-associated macrophages (TAMs) play a crucial role in tumor development and progression within the tumor microenvironment (*Pan et al., 2020*). Traditionally, TAMs have been associated with an immunosuppressive M2 phenotype, also known as M2-like TAMs, which is linked to more aggressive tumor behavior, including invasion, progression, and metastasis (*Pan et al., 2020; Zhou et al., 2020*). However, TAMs exhibit a spectrum of phenotypes, encompassing characteristics of both M2 and M1-like phenotypes (*Pan et al., 2020*).

| Table 1         Top 10 most up-regulated proteins in donor AB and O. |         |   |                                 |                             |  |
|--|---------|---|---------------------------------|-----------------------------|--|
| Donor  | Protein | Annotation  | Log <sub>2</sub><br>fold change | Adjusted<br><i>p</i> -value |  |
|  | P20930  | Filaggrin   | 6.276                           | 0.030038586                 |  |
|  | Q99541  | Perilipin-2 (Adipophilin)   | 4.938                           | 2.71943E-07                 |  |
|  | P63218  | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5                           | 3.605                           | 0.000122624                 |  |
|  | P14210  | Hepatocyte growth factor (Hepatopoietin-A)  | 3.514                           | 0.000190941                 |  |
|  | P62805  | Histone H4  | 3.285                           | 3.69662E-08                 |  |
| AB   | P56385  | ATP synthase subunit e, mitochondrial (ATPase subunit e)                                    | 3.211                           | 7.15786E-08                 |  |
|  | Q96IM9  | DPY30 domain-containing protein 2   | 3.176                           | 0.000494958                 |  |
|  | Q9BQA9  | Cytochrome b-245 chaperone 1  | 3.170                           | 5.69886E-05                 |  |
|  | Q13443  | Disintegrin and metalloproteinase domain-containing protein 9 (ADAM 9)                      | 3.011                           | 0.019705454                 |  |
|  | Q9Y446  | Plakophilin-3   | 2.879                           | 5.58355E-05                 |  |
|  | P00738  | Haptoglobin (Zonulin)   | 4.471                           | 0.002942747                 |  |
|  | Q8N441  | Fibroblast growth factor receptor-like 1 (FGF receptor-like protein 1)                      | 4.348                           | 1.10425E-05                 |  |
|  | Q00532  | Cyclin-dependent kinase-like 1  | 3.921                           | 7.68536E-06                 |  |
|  | P02749  | Beta-2-glycoprotein 1 (APC inhibitor) (Activated protein C-binding protein)                 | 3.468                           | 0.004052982                 |  |
|  | Q99541  | Perilipin-2 (Adipophilin)   | 3.464                           | 9.4512E-07                  |  |
| 0  | Q1KMD3  | Heterogeneous nuclear ribonucleoprotein U-like protein 2<br>(Scaffold-attachment factor A2) | 3.235                           | 0.015011281                 |  |
|  | Q96N67  | Dedicator of cytokinesis protein 7  | 3.209                           | 1.7831E-07                  |  |
|  | Q01130  | Serine/arginine-rich splicing factor 2 (Protein PR264)                                      | 3.161                           | 5.76301E-05                 |  |
|  | Q96A73  | Putative monooxygenase p33MONOX   | 3.127                           | 0.000474342                 |  |
|  | P54578  | Ubiquitin carboxyl-terminal hydrolase 14  | 2.991                           | 0.047368232                 |  |

*al.*, 2020; *Zhou et al.*, 2020). The M1-like TAMs possess antitumor properties and can selectively identify tumor cells while triggering mechanisms to eliminate them (*Pan et al.*, 2020; *Zhou et al.*, 2020). Clinical evidence suggests that higher levels of M2-like TAMs are associated with tumor progression and resistance to treatment, whereas higher levels of M1-like TAMs are correlated with positive outcomes to treatment (*Lv et al.*, 2022; *Oshi et al.*, 2020; *Zhang et al.*, 2014). Therefore, targeting the polarization state of TAMs by shifting the immunosuppressive M2 phenotype towards the tumoricidal M1-like TAM phenotype holds great promise for enhancing cancer therapies.

Oleamide, a fatty acid amide, is well-known for its sleep-inducing properties and involvement in CNS functions (*Boger, Henriksen & Cravatt, 1998; Maya-López et al., 2020; Mendelson & Basile, 2001; Verdon et al., 2000*). Recent studies have explored the anti-cancer potential of oleamide, particularly in MDA-MB-231 breast cancer cells, which are representative of triple-negative breast cancer (TNBC). TNBC is characterized by the absence of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2), making it less responsive to targeted therapies (*Kumar & Aggarwal, 2016*). Patients with TNBC often have poor prognoses, and survival rates after metastasis

| •     | Ũ       |  |                                 |                             |
|-------|---------|--|---------------------------------|-----------------------------|
| Donor | Protein | Annotation   | Log <sub>2</sub><br>fold change | Adjusted<br><i>p</i> -value |
|       | P14780  | Matrix metalloproteinase-9 (MMP-9)   | -3.489                          | 4.83496E-06                 |
|       | P30511  | HLA class I histocompatibility antigen, alpha chain F<br>(CDA12)           | -3.244                          | 8.27612E-07                 |
|       | Q14116  | Interleukin-18 (IL-18)   | -3.125                          | 0.000823613                 |
|       | Q13907  | Isopentenyl-diphosphate Delta-isomerase 1                                  | -3.087                          | 6.59727E-05                 |
|       | P12004  | Proliferating cell nuclear antigen (PCNA)                                  | -2.725                          | 3.81467E-05                 |
| AB    | O43150  | Arf-GAP with SH3 domain, ANK repeat and PH domain-<br>containing protein 2 | -2.683                          | 1.10482E-06                 |
|       | Q15582  | Transforming growth factor-beta-induced protein ig-h3<br>(Beta ig-h3)      | -2.653                          | 0.003999883                 |
|       | O60832  | H/ACA ribonucleoprotein complex subunit DKC1                               | -2.622                          | 0.001226448                 |
|       | P00390  | Glutathione reductase, mitochondrial (GR) (Grase)                          | -2.616                          | 1.4799E-05                  |
|       | Q9C002  | Normal mucosa of esophagus-specific gene 1 protein<br>(Protein FOAP-11)    | -2.522                          | 9.67433E-06                 |
|       | Q96IU4  | Putative protein-lysine deacylase ABHD14B                                  | -4.475                          | 0.006478591                 |
|       | Q460N5  | Protein mono-ADP-ribosyltransferase PARP14                                 | -3.641                          | 0.005335289                 |
|       | P60981  | Destrin (Actin-depolymerizing factor) (ADF)                                | -3.459                          | 3.97402E-05                 |
|       | P00441  | Superoxide dismutase [Cu-Zn]   | -3.154                          | 1.59527E-06                 |
|       | Q7Z3T8  | Zinc finger FYVE domain-containing protein 16 (Endofin)                    | -2.821                          | 0.00257461                  |
| 0     | Q8TBX8  | Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma                     | -2.694                          | 0.007376605                 |
|       | P04839  | Cytochrome b-245 heavy chain   | -2.688                          | 0.00097136                  |
|       | Q6P589  | Tumor necrosis factor alpha-induced protein 8-like protein 2 (TIPE2)       | -2.581                          | 3.62855E-06                 |
|       | Q16678  | Cytochrome P450 1B1  | -2.449                          | 0.000127442                 |
|       | Q14410  | Glycerol kinase 2 (GK 2)   | -2.440                          | 0.000376778                 |

#### Table 2 Top 10 most down-regulated proteins in donor AB and O.

 Table 3
 The top 10 significant terms annotated from up-regulated proteins with *p*-values and *q*-values for KEGG 2021 human library.

| Identifier | Term  | <i>p</i> -value | <i>q</i> -value | Overlap gene       |
|------------|---|-----------------|-----------------|--------------------|
| hsa05322   | Systemic lupus erythematosus                    | 0.0004          | 0.0187          | C3, FCGR2A, H2BC21 |
| hsa04613   | Neutrophil extracellular trap formation         | 0.0010          | 0.0248          | C3, FCGR2A, H2BC21 |
| hsa05140   | Leishmaniasis                                   | 0.0029          | 0.0421          | C3, FCGR2A         |
| hsa04610   | Complement and coagulation cascades             | 0.0036          | 0.0421          | C3, A2M            |
| hsa05150   | Staphylococcus aureus infection                 | 0.0044          | 0.0421          | C3, FCGR2A         |
| hsa00524   | Neomycin, kanamycin and gentamicin biosynthesis | 0.0052          | 0.0421          | HK2                |
| hsa04066   | HIF-1 signaling pathway                         | 0.0058          | 0.0421          | TF, HK2            |
| hsa04145   | Phagosome                                       | 0.0110          | 0.0699          | C3, FCGR2A         |
| hsa05152   | Tuberculosis                                    | 0.015119        | 0.085672        | C3, FCGR2A         |
| hsa00910   | Nitrogen metabolism                             | 0.017708        | 0.087929        | GLUL               |

are lower compared to other breast cancer subtypes (*Foulkes, Smith & Reis-Filho, 2010; Kumar & Aggarwal, 2016*). Consequently, the MDA-MB-231 cell line is frequently used as a model for highly aggressive and invasive breast cancer. In 2020, research demonstrated





| Table 4 | The top 10 significant terms annotate | d from down-regulated | proteins with <i>p</i> -values an | d <i>q</i> -values for KEGG 2021 human. |
|---------|---------------------------------------|-----------------------|-----------------------------------|---|
|---------|---------------------------------------|-----------------------|-----------------------------------|---|

| Identifier | Term                            | <i>p</i> -value | <i>q</i> -value | Overlap gene                       |
|------------|---------------------------------|-----------------|-----------------|------------------------------------|
| hsa05171   | Coronavirus disease             | 0.0001          | 0.0072          | RPS26, STAT2, RPL27A, RPLP1, RPS24 |
| hsa03010   | Ribosome                        | 0.0002          | 0.0107          | RPS26, RPL27A, RPLP1, RPS24        |
| hsa00190   | Oxidative phosphorylation       | 0.0022          | 0.0632          | PPA2, NDUFA10, UQCRH               |
| hsa00565   | Ether lipid metabolism          | 0.0041          | 0.0884          | PLA2G4A, PAFAH1B2                  |
| hsa00590   | Arachidonic acid metabolism     | 0.0063          | 0.1085          | PTGES3, PLA2G4A                    |
| hsa04664   | Fc epsilon RI signaling pathway | 0.0078          | 0.1115          | PLA2G4A, LCP2                      |
| hsa05012   | Parkinson disease               | 0.0125          | 0.1539          | NDUFA10, TXN, UQCRH                |
| hsa00564   | Glycerophospholipid metabolism  | 0.015653        | 0.152949        | LYPLA2, PLA2G4A                    |
| hsa05020   | Prion disease                   | 0.0160          | 0.1721          | NDUFA10, UQCRH, SOD1               |
| hsa05016   | Huntington disease              | 0.021599        | 0.170731        | NDUFA10, UQCRH, SOD1               |

that oleamide induces apoptosis and cell cycle arrest in MDA-MB-231 cells, highlighting its anti-cancer properties (*Wisitpongpun et al., 2020*). Furthermore, in 2022, oleamide was found to possess immunomodulatory effects, inducing the polarization of naïve primary human macrophages into M1 macrophages *via* the NLRP3 inflammasome pathway



Figure 9 Representative gene sets included those involved in the HIF-1 transcription factor (TF) pathway (A), as well as the regulation of insulin-like growth factor (IGF) transport and uptake *via* insulin-like growth factor binding proteins (IGFBPs) (B). The analysis demonstrated significant enrichment of differentially expressed genes (DEGs) in multiple gene sets, a complete list of enriched gene sets can be found in Files S2–S12.

Full-size DOI: 10.7717/peerj.18090/fig-9

#### Table 5 The statistical parameters of each gene set in oleamide-treated TAMs versus TAMs control.

| Gene set   | Enrichment<br>score<br>(ES) | Nominal<br><i>p</i> -value | False discovery<br>rate (FDR) <i>q</i> -value | Family-wise error<br>rate (FWER) |
|--|-----------------------------|----------------------------|---|----------------------------------|
| (Reactome) Regulation of insulin-like growth factor (IGF)<br>transport and uptake by insulin-like growth factor binding<br>proteins (IGFBPs) | 0.6716                      | 0.000                      | 0.0020  | 0.0020                           |
| (KEGG) Systemic lupus erythematosus  | 0.6334                      | 0.000                      | 0.0161  | 0.037                            |
| (PID) HIF-1 TF pathway   | 0.7341                      | 0.000                      | 0.0165  | 0.057                            |
| (Reactome) Response to elevated platelet cytosolic Ca <sup>2</sup>   | 0.5282                      | 0.000                      | 0.061   | 0.244                            |
| (Reactome) Transcriptional regulation by small RNAs  | 0.6900                      | 0.000                      | 0.0644  | 0.301                            |
| (Reactome) Gene silencing by RNAs  | 0.6838                      | 0.000                      | 0.0730  | 0.394                            |
| (Reactome) Rho GTPases activate PNKs   | 0.6475                      | 0.000                      | 0.0634  | 0.398                            |
| Reactome (Reproduction)  | 0.6712                      | 0.0030                     | 0.0793  | 0.524                            |
| (Semenza) HIF-1 targets  | 0.6649                      | 0.000                      | 0.0795  | 0.568                            |
| (WP) Sudden infant death syndrome (SIDs) susceptibility pathways   | 0.5762                      | 0.000                      | 0.0739  | 0.578                            |
| (Reactome) Chromatin modifying enzymes   | 0.5977                      | 0.0030                     | 0.0951  | 0.704                            |

#### Table 6 Molecular docking score of oleamide with selected proteins.

| No. | Protein name                                       | Docking<br>score | No. of<br>hydrogen<br>bond<br>formed | Interacting<br>amino acid<br>of OLA                                     |
|-----|--|------------------|--------------------------------------|---|
| 1   | Hexokinase-2                                       | -4.983           | 3                                    | PHE67, LYS162, LEU163, LEU463, ARG470, ASP814                           |
| 2   | Serine/threonine-protein kinase mTOR               | -6.166           | 1                                    | TYR26 PHE46 GLU54 TRP59 PHE128 TYR194                                   |
| 3   | Solute carrier family 2-member 1 (GLUT1)           | -5.833           | 3                                    | PHE26, THR30, ASN288, TRP388, TRP412, ASN415                            |
| 4   | Solute carrier family 2 member 4                   | -4.99            | 2                                    | THR78 ILE313 PHE438 GLN439 ALA442                                       |
| 5   | Hypoxia-inducible factor 1-alpha                   | -5.763           | 2                                    | TYR93 LEU101 TYR102 TYR103 LEU188 HIS199 PHE207<br>HIS279 ILE281 TRP296 |
| 6   | Transferrin receptor protein 1                     | -5.483           | 2                                    | THR192 PRO193 TRP523 TRP622   |
| 7   | Prostaglandin E synthase 3                         | -4.834           | 1                                    | PHE56 SER34 ILE53 LYS91 ALA94 LEU96                                     |
| 8   | Signal transducer and activator of transcription 2 | -5.379           | 2                                    | GLU139 GLN142 LYS234 TRP238 LEU258 TRP261                               |
| 9   | Nucleosome assembly protein 1 like 1               | -7.052           | 2                                    | PHE95 ALA107 TYR110 GLN111 VAL201 PHE203 ILE335<br>PRO336               |

(*Wisitpongpun, Potup & Usuwanthim, 2022*). This is significant as M1 macrophages play a crucial role in bacterial clearance, inflammation induction, and anti-cancer activity, particularly in the context of M1-like tumor-associated macrophages (TAMs) (*Pan et al., 2020*; *Zhou et al., 2020*).

However, the regulatory effects of oleamide on human TAM polarization and its impact on cancer progression remain unexplored. In this study, we aimed to investigate the ability of oleamide to reprogram M2-like TAMs towards tumoricidal M1-like phenotypes using a transwell co-culture model of primary human MDMs and MDA-MB-231 cells.



Figure 10 Molecular docking analysis of selected upregulated and downregulated proteins. Full-size DOI: 10.7717/peerj.18090/fig-10

We selected the MDA-MB-231 cell line for this study for several compelling reasons. Previous research has specifically demonstrated the anti-cancer effects of oleamide against MDA-MB-231 cells, making it an appropriate and relevant model for further investigation. Moreover, the MDA-MB-231 cell line is extensively utilized in the generation of TAMs by co-culturing the culture medium with THP-1 cells (*Benner et al., 2019; Hollmén et al., 2015; Pe et al., 2022*). These provided a reliable model for our investigation into the reprogramming potential of oleamide on TAMs.

From Transwell co-culture, we observed that low dose of oleamide treatment led to the suppression of IL-10 production and downregulation of *VEGFA*, *c-Myc*, and *CD206* expressions, while inducing the expression of the *HLA-DR*. Additionally, proteomic analysis identified 20 candidate proteins that play pivotal roles in oleamide-mediated regulation of M1 macrophage polarization.

To establish an in vitro model for studying TAM functions, we employed a modified protocol for the generation of TAMs from peripheral blood human monocytes using a Transwell co-culture with MDA-MB-231 breast cancer cells (Fig. 1). Our findings revealed that co-culturing human monocytes with MDA-MB-231 cells in the presence of M-CSF, IL-4, and IL-10 strongly induced the expression of *c-Myc*, VEGFA, MMP-9, and CD206 genes. Furthermore, co-culture of monocytes and MDA-MB-231 cells in a complete medium promoted the polarization of monocytes towards M2-like TAM phenotypes, as evidenced by upregulated expression of MMP-9 and VEGFA, while c-Myc and CD206 gene expressions remained unaltered. These findings are consistent with previous studies, including the work by Hollmén et al. (2015) which demonstrated that MDA-MB-231 cells can induce the differentiation of human monocytes into M2-like macrophages, characterized by increased macrophage mannose receptor (MMR) protein expression and C-C motif chemokine ligand 2 (CCL2) secretion, using a Transwell co-culture system. However, it should be noted that TAM activation also involves T-helper 2 cytokines such as IL-4 and IL-13, as well as immunosuppressive cytokines like IL-10 and transforming growth factor beta (TGF- $\beta$ ), indicating the need for additional cytokines for the full differentiation of TAMs.

To generate TAM-like cells, the cultivation of monocytes in tumor-conditioned medium is a commonly employed and straightforward method. We co-cultured monocytes and MDA-MB-231 cells using a 1:1 ratio of tumor-conditioned medium to complete medium, supplemented with M-CSF, IL-4, and IL-10. Notably, co-culturing monocytes in complete medium with cytokines resulted in a more significant increase in the expression of *c-Myc*, *VEGFA*, *MMP9*, and *CD206* genes compared to co-culturing with tumor-conditioned medium (Fig. 2B). This suggests that the addition of tumor-conditioned medium is not essential for generating TAMs using our Transwell co-culture model. Overall, our findings indicate that the Transwell co-culture approach, along with the inclusion of M-CSF, IL-4, and IL-10, is an effective strategy for *in vitro* TAM production.

Oleamide, also known as cis-9,10-octadecenoamide, belongs to a class of endogenous lipid signaling molecules and was initially recognized for its sleep-inducing properties (*Boger, Henriksen & Cravatt, 1998*). Subsequently, oleamide was identified as a neuromodulator that interacts with various neurotransmitter receptors, including

those for dopamine, acetylcholine, serotonin, gamma-aminobutyric acid (GABA), and cannabinoids (Boger, Henriksen & Cravatt, 1998; Maya-López et al., 2020; Mendelson & Basile, 2001; Verdon et al., 2000). Moreover, oleamide possesses anticancer properties, inducing apoptosis in different cancer cell lines, such as MDA-MB-231 breast cancer cells, SSC-15 squamous cell carcinoma, and K-562 myelogenous leukemia cells (Wisitpongpun et al., 2020). Recent studies have also demonstrated the immunomodulatory activity of oleamide by promoting M1 macrophage polarization in primary human macrophages (Wisitpongpun, Potup & Usuwanthim, 2022). Building upon these reports, we investigated the effect of oleamide (20 µg/ml) on TAM polarization. Our study revealed that oleamide treatment induced the reprogramming of M2-like TAMs towards M1-like TAM phenotypes, as evidenced by the suppression of *c-Myc*, VEGFA, and CD206 gene expressions, along with the upregulation of HLA-DR, a gene associated with M1-like TAMs (Fig. 3A). This concentration was shown to be non-toxic to cancer cells (Fig. 4A). Generally, M1-like TAMs are characterized by the secretion of pro-inflammatory cytokines such as IL-6, IL-12, IL-23, and TNF- $\alpha$ , which contribute to pro-inflammatory activities (Zheng et al., 2017). Conversely, M2-like TAMs exhibit high expression levels of immunosuppressive molecules, including IL-10, TGF- $\beta$ , and programmed death-ligand 1 (PD-L1), which are associated with cancer progression. Notably, our results demonstrated that oleamide-treated TAMs suppressed the production of IL-10 (Fig. 3B), supporting the notion that oleamide promotes M1-like TAM polarization.

M1-like TAMs exhibit anti-tumorigenic properties and employ multiple mechanisms to recognize and eliminate tumor cells. These mechanisms include direct killing through the release of mediators including tumor necrosis factor (TNF), nitric oxide (NO), and reactive oxygen species (ROS), as well as phagocytosis of cancer cells. Additionally, M1-like TAMs can induce cancer cell cytolysis *via* antibody-dependent cellular cytotoxicity (ADCC) and activate other immune cells such as natural killer (NK) cells and T cells (*Aminin & Wang, 2021; Pan et al., 2020; Zhou et al., 2020*). Intriguingly, we found that conditioned medium obtained from 20  $\mu$ g/ml oleamide-treated TAMs suppressed the proliferation of MDA-MB-231 cells at 24 and 48 h (Fig. 4A). Flow cytometry analysis revealed that the conditioned medium from oleamide-treated TAMs induced apoptosis in MDA-MB-231 cells after 24 h of treatment, while these 20  $\mu$ g/ml oleamide alone did not significantly impact cell apoptosis (Fig. 4B). The evidence presented here suggests that the conditioned medium collected from oleamide-treated TAMs contains mediators against MDA-MB-231 cells. However, the precise molecular mechanisms underpinning this process remain elusive.

Prior research has indicated that IL-1  $\beta$  can trigger apoptosis in various cell types by upregulating the proapoptotic protein Bax and downregulating the antiapoptotic protein Bcl-2 (*Chauhan et al., 2018*; *Wang et al., 2023*). Given that our findings reveal increased IL-1  $\beta$  production in oleamide-treated TAMs, it is plausible that this could contribute to the apoptosis of MDA-MB-231 cells. However, further investigations are imperative to substantiate this hypothesis. Furthermore, MDA-MB-231 cells, categorized as triple-negative breast cancer (TNBC) cells, lack expression of estrogen receptor (ER) and progesterone receptor (PR), and also lack human epidermal growth factor receptor 2 (HER2) amplification. Consequently, MDA-MB-231 cells exhibit a significantly elevated metastatic potential and aggressiveness compared to MCF-7 (ER positive) breast cancer cells (*Gest et al., 2013; Shi, Ye & Long, 2017*). Consequently, the observed anti-cancer activity of oleamide-treated TAMs might potentially translate to success in MCF-7 cells as well. However, this hypothesis necessitates a more comprehensive investigation for confirmation, as well as for elucidating the mechanisms underlying this phenomenon across various cancer cell types.

Our proteomic analysis conducted uncovered several significant proteins that potentially contribute to macrophage polarization. Among the up-regulated proteins were those involved in phagocytosis, a key role of M1 macrophages. Notably, complement C3 (C3) and low affinity immunoglobulin gamma Fc region receptor II-a (Fc  $\gamma$  RIIa) were up-regulated. Complement C3 is a key protein in the innate immune system and plays a critical role in coordinating various immune responses, including pathogen clearance, tissue regeneration, and control of tumor cell progression (*Ricklin et al.*, 2016). A correlation between the upregulation of C3 and its receptor with an increase in M1 macrophage polarization has been reported (Bohlson et al., 2014; Ghate et al., 2021; Luo et al., 2012; Ruan et al., 2015). Additionally, the upregulation of Fc  $\gamma$  RIIa indicates an enhancement in phagocytic activity. Fc  $\gamma$  RIIa is a member of the human Fc  $\gamma$  RII receptor family and its activation can stimulate or regulate various effector functions of leukocytes during immune responses, such as the clearance of opsonized antigens and the production of pro-inflammatory cytokines (Anania et al., 2019). Upregulation of Fc  $\gamma$  RIIa suggests an improved ability to perform phagocytosis, which is a fundamental function of M1 macrophages (Crowley et al., 1997; Lu et al., 2008; Strzelecka, Kwiatkowska & Sobota, 1997). Furthermore, oleamide treatment led to the upregulation of other proteins, including transferrin (TF), transferrin receptor (TFRC), hexokinase-1 (HK1), and hexokinase-2 (HK2).

Transferrin (TF), an iron-binding transport protein, has been implicated in iron metabolism during M1-macrophage polarization (Agoro et al., 2018; Cairo et al., 2011; Handa et al., 2019; Hu et al., 2019; Jung, Mertens & Brüne, 2015; Xia et al., 2021). Increased iron uptake increases the expression of M1 markers, including iNOS, IL-1 $\beta$ , IL-6, and TNF- $\alpha$ , while concurrently reducing the expression of M2 markers (*Handa et al., 2019*). Docking analysis indicate a favorable binding score of -5.483 kcal/mol between oleamide and transferrin receptor 1, coupled with an observed increase in transferrin expression. These observations suggest that oleamide has the potential to promote the polarization of M1-like tumor-associated macrophages (TAMs) through its effects on iron metabolism. In RAW246.7 cells, overexpression of glucose transporter 1 (GLUT1), the primary ratelimiting glucose transporter, resulted in increased production of pro-inflammatory mediators and reactive oxygen species (ROS) upon LPS stimulation (Freemerman et al., 2014). A previous study by Moon et al. (2015) demonstrated that LPS stimulation triggered upregulation of glycolysis, enhanced cell adhesion, and elevated accumulation of reactive oxygen species (ROS). This effect was mediated by mechanistic target of rapamycin kinase (mTOR)-induced upregulation of GLUT1. Furthermore, it is worth noting that glycolysis can be influenced by iron metabolism. A study utilizing murine bone marrow-derived macrophages (BMDMs) loaded with ferric ammonium citrate

(FAC) demonstrated enhanced pro-inflammatory phenotypes along with an increase in both the basic and maximal extracellular acidification rate (ECAR), while the oxygen consumption rate (OCR) remained unchanged (Hu et al., 2019). Previous investigations have consistently highlighted the strong association between increased glycolysis and M1 macrophage polarization. This relationship is regulated by the hypoxia-inducible factor- $1\alpha$ (HIF-1 $\alpha$ ) transcription factor (*Li et al.*, 2018; *Wang et al.*, 2017; *Woods et al.*, 2022). HIF-1 serves as a key transcription factor involved in metabolic adaptation under conditions of low oxygen and nutrient deprivation (Weidemann & Johnson, 2008). In our study, oleamide treatment of TAMs induced the expression of hexokinase-2 (HK2) proteins, indicating enhanced glycolytic activity. Additionally, docking analysis revealed favorable binding scores of -6.166 and -5.833 kcal/mol between oleamide and serine/threonine-protein kinase mTOR (MTOR) and glucose transporter 1 (GLUT1), respectively (Fig. 10 and Table 6). These findings suggest the potential interaction of oleamide in promoting M1-like TAMs through upregulation of the glycolytic pathway. Additional investigations are therefore warranted to elucidate the molecular mechanisms underlying the role of oleamide in promoting M1 macrophage polarization.

Among the down-regulated proteins, a notable decrease was observed in ribosomal proteins (PRs), which play an essential role in controlling cell growth and survival by regulating protein synthesis (Kang et al., 2021). Specifically, oleamide treatment reduced expression of the 40S ribosomal protein S24 (RPS24) and the 60S acidic ribosomal protein P1 (RPLP1). While the implication of ribosomal proteins in macrophage polarization is not clearly established, they are associated with diverse aspects of cellular growth, proliferation, and malignancy (De las Heras-Rubio et al., 2014; Elhamamsy et al., 2022; Kang et al., 2021; Van Riggelen, Yetil & Felsher, 2010). RPS24 is highly expressed in prostate cancer, colorectal cancer, and hepatocellular carcinoma, where it is implicated in driving tumor progression (Arthurs et al., 2017; Elhamamsy et al., 2022; Li et al., 2023; Wang et al., 2015). Furthermore, a recent study demonstrated that inhibiting RPS24 expression using small hairpin shRNA can suppress cell proliferation and migration in colon cancer (Wang et al., 2015). Similarly, RPLP1, a component of the 60S ribosomal subunit, is proposed to play a role in diseases associated with cell proliferation and survival (*Alali et al., 2020*; Martinez-Azorin, Remacha & Ballesta, 2008). Overexpression of RPLP1 has been observed in hepatocellular carcinoma and triple-negative breast cancer and associated with a poor prognosis (Barnes et al., 2016; He et al., 2018). Our collective findings provide evidence that oleamide may inhibit the proliferation and progression of TAMs. However, further research is necessary to substantiate this claim.

Additionally, other proteins that were down-regulated included signal transducer and activator of transcription 2 (STAT2), prostaglandin E synthase 3 (PTGES3), and nucleosome assembly protein 1-like 1 (NAP1L1). STAT2 is an essential transcription factor involved in type I interferon (IFN- $\alpha/\beta$ )-mediated anti-viral and anti-proliferative signaling (*Steen & Gamero, 2013*). Generally, STAT1 and STAT2 are implicated in LPS-mediated M1 polarization through the activation of TLR4 (*Steen & Gamero, 2013*; *Tugal, Liao & Jain, 2013*). In response to LPS, autocrine production of IFN- $\beta$  activates the type I IFN receptor, leading to the phosphorylation of STAT1 and STAT2, and ultimately increased production of type II interferon (IFN-γ) (Ivashkiv & Donlin, 2014; Tugal, Liao & Jain, 2013). IFN-γ was the first cytokine identified to induce M1 polarization (Ivashkiv, 2018). Our results indicate that the ability of oleamide to promote the differentiation of M1-like TAMs might not be exclusively mediated by IFN- $\gamma$  signaling. However, more research is necessary to confirm this statement, and the determination of IFN- $\gamma$  levels could provide valuable support. Remarkably, NAP1L1 is a critical member of the nucleosome assembly protein (NAP) family and has garnered significant attention in various tumor types, including lung adenocarcinoma, glioblastoma, colorectal cancer, and breast cancer (Aydin et al., 2020; Nagashio et al., 2020; Queiroz et al., 2020; Zottel et al., 2020). Recent studies have demonstrated a correlation between NAPL1 expression and immune cells, suggesting its role in promoting hepatocellular carcinoma progression via the Wnt/ $\beta$ -catenin pathway (*Shen et al.*, 2022). Activation of the Wnt/ $\beta$ -catenin pathway has been reported to promote macrophage M2 polarization (Yang et al., 2018). In this context, oleamide may have the potential to suppress M2-like TAMs by inhibiting NAP1L1-induced Wnt/ $\beta$ -catenin activation. Notably, docking analysis of NAP1L1 exhibited the most favorable binding score to oleamide, with a value of -7.052 kcal/mol among all the proteins assessed (Fig. 10 and Table 6). Therefore, NAP1L1 emerges as a promising and intriguing target of oleamide for modulating TAM polarization. Our study elucidates the molecular mechanisms by which oleamide promotes the polarization of TAMs towards the M1 phenotype, potentially leading to the inhibition of breast cancer progression. This finding highlights the novel therapeutic potential of using oleamide to modulate TAM phenotype within the tumor microenvironment, opening avenues for future in vivo and clinical investigations in combination cancer therapy.

This study has several limitations. Firstly, the characterization of monocyte-derived TAM phenotypes was based solely on gene expression profiles, which may not provide a complete and accurate representation of TAM phenotypes. Incorporating the analysis of surface marker expressions using flow cytometry would enhance the reliability of TAM phenotype characterization. Additionally, due to limited medium volume and the use of conventional ELISA, we could not measure multiple cytokines simultaneously, restricting our cytokine profile. Future studies should include additional cytokines like IL-12 and VEGFA for a more comprehensive analysis.

One significant limitation is the exclusive use of the MDA-MB-231 cell line, representative of TNBC. This choice does not encompass other breast cancer subtypes, such as ER positive, PR positive, and HER2 positive subtypes. Each subtype has distinct biological behaviors and responses to treatment, which may affect the polarization of TAMs differently. To provide a more comprehensive understanding, future studies should include co-culture experiments with a variety of breast cancer cell lines, such as MCF-7 (ER positive), T47D (PR positive), and SK-BR-3 (HER2 overexpressing) (*Dai et al., 2017*).

Additionally, our study utilized a simplified transwell co-culture model to investigate the interaction between oleamide, TAMs, and cancer cells. This model does not fully capture the complexity of the tumor microenvironment, which includes various cell types, extracellular matrix components, and soluble factors (*Xiao, Wang & Peng, 2023*). These

elements can significantly influence cancer progression and macrophage polarization, potentially affecting the observed outcomes (*Xiao*, *Wang & Peng*, 2023).

The proteomic analysis was conducted using whole cell lysate proteins, which may not capture the full spectrum of secreted proteins. As a result, proteins secreted into the supernatant may have been missed, potentially limiting the comprehensive understanding of the TAM proteome. Verification of candidate proteins identified through proteomic analysis should be validated through *in vitro* and/or *in vivo* experiments. Furthermore, in-depth molecular mechanistic studies are required to elucidate how oleamide mediates TAM polarization and the mechanisms responsible for the inhibition of cell viability and induction of apoptosis in MDA-MB-231 cells by the cultured medium from oleamidetreated TAMs. However, in order to ascertain and gather complete data, the number of blood group samples possesses to be augmented.

### **CONCLUSIONS**

This study suggested that oleamide holds promise in promoting M1-like phenotype in TAMs, indicating its potential as a therapeutic target in cancer treatment. Proteomic analysis and molecular docking revealed candidate proteins targeted by oleamide, highlighting its potential for TAM polarization. The findings provide valuable resources for further investigations into oleamide and macrophage polarization using primary human monocyte-TAM models. Future research can be expected to elucidate the mechanisms underlying the effects more fully of oleamide on TAM polarization and its potential clinical applications.

### ACKNOWLEDGEMENTS

We would like to thank the staff of the Blood Bank Unit of Naresuan University Hospital, Thailand for providing blood samples.

## **ADDITIONAL INFORMATION AND DECLARATIONS**

### Funding

This research was funded by the Royal Golden Jubilee Ph.D. Program (Grant No. PhD/0002/2559), the Thailand Science Research and Innovation, and Naresuan University (R2567B041) and the Reinventing University Program 2023, The Ministry of Higher Education, Science, Research and Innovation (MHESI), Thailand (R2566A054). There was no additional external funding received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

### **Grant Disclosures**

The following grant information was disclosed by the authors: Royal Golden Jubilee Ph.D. Program: PhD/0002/2559. Thailand Science Research and Innovation, and Naresuan University: R2567B041. Reinventing University Program 2023. The Ministry of Higher Education, Science, Research and Innovation (MHESI), Thailand: R2566A054.

### **Competing Interests**

The authors declare there are no competing interests.

### **Author Contributions**

- Prapakorn Wisitpongpun conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the article, and approved the final draft.
- Watunyoo Buakaew conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the article, and approved the final draft.
- Sutatip Pongcharoen conceived and designed the experiments, authored or reviewed drafts of the article, and approved the final draft.
- Napaporn Apiratmateekul conceived and designed the experiments, authored or reviewed drafts of the article, and approved the final draft.
- Pachuen Potup conceived and designed the experiments, authored or reviewed drafts of the article, and approved the final draft.
- Krai Daowtak conceived and designed the experiments, authored or reviewed drafts of the article, and approved the final draft.
- Sucheewin Krobthong conceived and designed the experiments, analyzed the data, authored or reviewed drafts of the article, and approved the final draft.
- Yodying Yingchutrakul conceived and designed the experiments, analyzed the data, authored or reviewed drafts of the article, and approved the final draft.
- Paul J. Brindley conceived and designed the experiments, authored or reviewed drafts of the article, and approved the final draft.
- Kanchana Usuwanthim conceived and designed the experiments, analyzed the data, authored or reviewed drafts of the article, and approved the final draft.

### **Human Ethics**

The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

This study was approved by the Naresuan University institutional review board (IRB No.0172/62).

### **Data Availability**

The following information was supplied regarding data availability:

The proteomic raw data is available at PRIDE: PXD043461.

The raw data (Figs. 2–4) are available at figshare: Wisitpongpun, Prapakorn (2024). Proteomic Profiling and Functional Analysis of Oleamide-Mediated Polarization in a Primary Human Monocyte-Derived TAMs Model. figshare. Journal contribution. https://doi.org/10.6084/m9.figshare.25331530.v1.

The raw data of flow cytometry is available at flow repository: FR-FCM-Z782. http://flowrepository.org/id/FR-FCM-Z782.

### **Supplemental Information**

Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.18090#supplemental-information.

### REFERENCES

- Agoro R, Taleb M, Quesniaux VFJ, Mura C. 2018. Cell iron status influences macrophage polarization. *PLOS ONE* 13:e0196921 DOI 10.1371/journal.pone.0196921.
- Alali Z, Graham A, Swan K, Flyckt R, Falcone T, Cui W, Yang X, Christianson J, Nothnick WB. 2020. 60S acidic ribosomal protein P1 (RPLP1) is elevated in human endometriotic tissue and in a murine model of endometriosis and is essential for endometriotic epithelial cell survival in vitro. *Molecular Human Reproduction* 26:53–64 DOI 10.1093/molehr/gaz065.
- Aminin D, Wang Y-M. 2021. Macrophages as a weapon in anticancer cellular immunotherapy. *The Kaohsiung Journal of Medical Sciences* 37:749–758 DOI 10.1002/kjm2.12405.
- **Anania JC, Chenoweth AM, Wines BD, Hogarth PM. 2019.** The human Fc γ RII (CD32) family of Leukocyte FcR in health and disease. *Frontiers in Immunology* **10**:464 DOI 10.3389/fimmu.2019.00464.
- Ano Y, Ozawa M, Kutsukake T, Sugiyama S, Uchida K, Yoshida A, Nakayama H. 2015. Preventive effects of a fermented dairy product against Alzheimer's disease and identification of a novel oleamide with enhanced microglial phagocytosis and antiinflammatory activity. *PLOS ONE* **10**:e0118512 DOI 10.1371/journal.pone.0118512.
- Arthurs C, Murtaza BN, Thomson C, Dickens K, Henrique R, Patel HRH, Beltran M, Millar M, Thrasivoulou C, Ahmed A. 2017. Expression of ribosomal proteins in normal and cancerous human prostate tissue. *PLOS ONE* 12:e0186047 DOI 10.1371/journal.pone.0186047.
- Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G. 2000. Gene ontology: tool for the unification of biology. *Nature Genetics* 25:25–29 DOI 10.1038/75556.
- Aydin MA, Gul G, Kiziltan R, Algul S, Kemik O. 2020. Nucleosome assembly protein 1-like 1 (NAP1L1) in colon cancer patients: a potential biomarker with diagnostic and prognostic utility. *European Review for Medical and Pharmacological Sciences* 24:10512–10517 DOI 10.26355/eurrey\_202010\_23403.
- Barnes DJ, Hookway E, Athanasou N, Kashima T, Oppermann U, Hughes S, Swan D, Lueerssen D, Anson J, Hassan AB. 2016. A germline mutation of CDKN2A and a novel RPLP1-C19MC fusion detected in a rare melanotic neuroectodermal tumor of infancy: a case report. *BMC Cancer* 16:629 DOI 10.1186/s12885-016-2669-3.
- Benner B, Scarberry L, Suarez-Kelly LP, Duggan MC, Campbell AR, Smith E, Lapurga G, Jiang K, Butchar JP, Tridandapani S, Howard JH, Baiocchi RA, Mace

**TA, Carson 3rd WE. 2019.** Generation of monocyte-derived tumor-associated macrophages using tumor-conditioned media provides a novel method to study tumor-associated macrophages in vitro. *The Journal for ImmunoTherapy of Cancer* 7:140 DOI 10.1186/s40425-019-0622-0.

- **Boger DL, Henriksen SJ, Cravatt BF. 1998.** Oleamide: an endogenous sleep-inducing lipid and prototypical member of a new class of biological signaling molecules. *Current Pharmaceutical Design* **4**:303–314 DOI 10.2174/138161280404221010152220.
- Bohlson S, O'Conner S, Hulsebus H, Minh N, Fraser D. 2014. Complement, C1q, and C1q-related molecules regulate macrophage polarization. *Frontiers in Immunology* 5:402 DOI 10.3389/fimmu.2014.00402.
- Cairo G, Recalcati S, Mantovani A, Locati M. 2011. Iron trafficking and metabolism in macrophages: contribution to the polarized phenotype. *Trends in Immunology* 32:241–247 DOI 10.1016/j.it.2011.03.007.
- Chauhan D, Bartok E, Gaidt MM, Bock FJ, Herrmann J, Seeger JM, Broz P, Beckmann R, Kashkar H, Tait SWG, Müller R, Hornung V. 2018. BAX/BAK-induced apoptosis results in caspase-8-dependent IL-1 β maturation in macrophages. *Cell Reports* 25:2354–2368.e2355 DOI 10.1016/j.celrep.2018.10.087.
- Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, Clark NR, Ma'ayan A. 2013. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. *BMC Bioinformatics* 14:128 DOI 10.1186/1471-2105-14-128.
- **Crowley MT, Costello PS, Fitzer-Attas CJ, Turner M, Meng F, Lowell C, Tybulewicz VLJ, De Franco AL. 1997.** A critical role for syk in signal transduction and phagocytosis mediated by Fc γ receptors on macrophages. *Journal of Experimental Medicine* **186**:1027–1039 DOI 10.1084/jem.186.7.1027.
- Dai X, Cheng H, Bai Z, Li J. 2017. Breast cancer cell line classification and its relevance with breast tumor subtyping. *Journal of Cancer* 8:3131–3141 DOI 10.7150/jca.18457.
- De las Heras-Rubio A, Perucho L, Paciucci R, Vilardell J, Lleonart ME. 2014. Ribosomal proteins as novel players in tumorigenesis. *Cancer and Metastasis Reviews* 33:115–141 DOI 10.1007/s10555-013-9460-6.
- De Zoete MR, Palm NW, Zhu S, Flavell RA. 2014. Inflammasomes. *Cold Spring Harbor Perspectives in Biology* 6:016287 DOI 10.1101/cshperspect.a016287.
- Eberhardt J, Santos-Martins D, Tillack AF, Forli S. 2021. AutoDock Vina 1.2.0: new docking methods, expanded force field, and python bindings. *Journal of Chemical Information and Modeling* 61:3891–3898 DOI 10.1021/acs.jcim.1c00203.
- Elhamamsy AR, Metge BJ, Alsheikh HA, Shevde LA, Samant RS. 2022. Ribosome biogenesis: a central player in cancer metastasis and therapeutic resistance. *Cancer Research* 82:2344–2353 DOI 10.1158/0008-5472.Can-21-4087.
- **Foulkes WD, Smith IE, Reis-Filho JS. 2010.** Triple-negative breast cancer. *The New England Journal of Medicine* **363**:1938–1948 DOI 10.1056/NEJMra1001389.
- Fowler CJ. 2004. Oleamide: a member of the endocannabinoid family? *British Journal of Pharmacology* 141:195–196 DOI 10.1038/sj.bjp.0705608.
- Freemerman AJ, Johnson AR, Sacks GN, Milner JJ, Kirk EL, Troester MA, Macintyre AN, Goraksha-Hicks P, Rathmell JC, Makowski L. 2014. Metabolic reprogramming

of macrophages: glucose transporter 1 (GLUT1)-mediated glucose metabolism drives a proinflammatory phenotype. *Journal of Biological Chemistry* **289**:7884–7896 DOI 10.1074/jbc.M113.522037.

- **Gaillard T. 2018.** Evaluation of autodock and autodock vina on the CASF-2013 benchmark. *Journal of Chemical Information and Modeling* **58**:1697–1706 DOI 10.1021/acs.jcim.8b00312.
- Gest C, Joimel U, Huang L, Pritchard L-L, Petit A, Dulong C, Buquet C, Hu C-Q, Mirshahi P, Laurent M, Fauvel-Lafève F, Cazin L, Vannier J-P, Lu H, Soria J, Li H, Varin R, Soria C. 2013. Rac3 induces a molecular pathway triggering breast cancer cell aggressiveness: differences in MDA-MB-231 and MCF-7 breast cancer cell lines. *BMC Cancer* 13:63 DOI 10.1186/1471-2407-13-63.
- Ghate A, Sharma S, Agrawal P, Sahu A. 2021. Differential expression of complement receptors CR1/2 and CR4 by murine M1 and M2 macrophages. *Molecular Immunology* 137:75–83 DOI 10.1016/j.molimm.2021.06.003.
- Gordon S, Plüddemann A. 2017. Tissue macrophages: heterogeneity and functions. *BMC Biology* 15:53 DOI 10.1186/s12915-017-0392-4.
- Griss J, Viteri G, Sidiropoulos K, Nguyen V, Fabregat A, Hermjakob H. 2020. ReactomeGSA - efficient multi-omics comparative pathway analysis. *Molecular & Cellular Proteomics* 19:2115–2125 DOI 10.1074/mcp.TIR120.002155.
- Handa P, Thomas S, Morgan-Stevenson V, Maliken BD, Gochanour E, Boukhar S, Yeh MM, Kowdley KV. 2019. Iron alters macrophage polarization status and leads to steatohepatitis and fibrogenesis. *Journal of Leukocyte Biology* 105:1015–1026 DOI 10.1002/JLB.3A0318-108R.
- He Z, Xu Q, Wang X, Wang J, Mu X, Cai Y, Qian Y, Shao W, Shao Z. 2018. RPLP1 promotes tumor metastasis and is associated with a poor prognosis in triple-negative breast cancer patients. *Cancer Cell International* 18:170 DOI 10.1186/s12935-018-0658-0.
- Hollmén M, Roudnicky F, Karaman S, Detmar M. 2015. Characterization of macrophage cancer cell crosstalk in estrogen receptor positive and triple-negative breast cancer. *Scientific Reports* 5:9188 DOI 10.1038/srep09188.
- Hu X, Cai X, Ma R, Fu W, Zhang C, Du X. 2019. Iron-load exacerbates the severity of atherosclerosis via inducing inflammation and enhancing the glycolysis in macrophages. *Journal of Cellular Physiology* 234:18792–18800 DOI 10.1002/jcp.28518.
- **Ivashkiv LB. 2018.** IFN  $\gamma$ : signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. *Nature Reviews Immunology* **18**:545–558 DOI 10.1038/s41577-018-0029-z.
- Ivashkiv LB, Donlin LT. 2014. Regulation of type I interferon responses. *Nature Reviews Immunology* 14:36–49 DOI 10.1038/nri3581.
- Jung M, Mertens C, Brüne B. 2015. Macrophage iron homeostasis and polarization in the context of cancer. *Immunobiology* 220:295–304 DOI 10.1016/j.imbio.2014.09.011.
- **Kanehisa M. 2019.** Toward understanding the origin and evolution of cellular organisms. *Protein Science* **28**:1947–1951 DOI 10.1002/pro.3715.

- Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. 2023. KEGG for taxonomy-based analysis of pathways and genomes. *Nucleic Acids Research* 51:D587–D592 DOI 10.1093/nar/gkac963.
- Kanehisa M, Goto S. 2000. KEGG: Kyoto encyclopedia of genes and genomes. *Nucleic Acids Research* 28:27–30 DOI 10.1093/nar/28.1.27.
- Kang J, Brajanovski N, Chan KT, Xuan J, Pearson RB, Sanij E. 2021. Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy. *Signal Transduction and Targeted Therapy* **6**:323 DOI 10.1038/s41392-021-00728-8.
- Krobthong S, Yingchutrakul Y, Samutrtai P, Hitakarun A, Siripattanapipong S, Leelayoova S, Mungthin M, Choowongkomon K. 2022. Utilizing quantitative proteomics to identify species-specific protein therapeutic targets for the treatment of leishmaniasis. *ACS Omega* 7:12580–12588 DOI 10.1021/acsomega.1c05792.
- Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, Koplev S, Jenkins SL, Jagodnik KM, Lachmann A, McDermott MG, Monteiro CD, Gundersen GW, Ma'ayan A. 2016. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. *Nucleic Acids Research* 44:W90–W97 DOI 10.1093/nar/gkw377.
- Kumar P, Aggarwal R. 2016. An overview of triple-negative breast cancer. *Archives of Gynecology and Obstetrics* 293:247–269 DOI 10.1007/s00404-015-3859-y.
- Li C, Wang Y, Li Y, Yu Q, Jin X, Wang X, Jia A, Hu Y, Han L, Wang J, Yang H, Yan D, Bi Y, Liu G. 2018. HIF-1 α-dependent glycolysis promotes macrophage functional activities in protecting against bacterial and fungal infection. *Scientific Reports* 8:3603 DOI 10.1038/s41598-018-22039-9.
- Li H, Gao L, Kang X, Wang X, Yu Y, Zhang Y, Chen H. 2023. RPS24 is associated with a poor prognosis and immune infiltration in hepatocellular carcinoma. *International Journal of Molecular Sciences* 24:806 DOI 10.3390/ijms24010806.
- Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov Jill P, Tamayo P. 2015. The molecular signatures database hallmark gene set collection. *Cell Systems* 1:417–425 DOI 10.1016/j.cels.2015.12.004.
- Liberzon A, Subramanian A, Pinchback R, Thorvaldsdóttir H, Tamayo P, Mesirov JP. 2011. Molecular signatures database (MSigDB) 3.0. *Bioinformatics* 27:1739–1740 DOI 10.1093/bioinformatics/btr260.
- Lu J, Marnell LL, Marjon KD, Mold C, Du Clos TW, Sun PD. 2008. Structural recognition and functional activation of Fc γR by innate pentraxins. *Nature* **456**:989–992 DOI 10.1038/nature07468.
- Luo C, Chen M, Madden A, Xu H. 2012. Expression of complement components and regulators by different subtypes of bone marrow-derived macrophages. *Inflammation* 35:1448–1461 DOI 10.1007/s10753-012-9458-1.
- Lv C, Li S, Zhao J, Yang P, Yang C. 2022. M1 macrophages enhance survival and invasion of oral squamous cell carcinoma by inducing GDF15-mediated ErbB2 phosphorylation. *ACS Omega* 7:11405–11414 DOI 10.1021/acsomega.2c00571.

- Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. 2004. The chemokine system in diverse forms of macrophage activation and polarization. *Trends in Immunology* 25:677–686 DOI 10.1016/j.it.2004.09.015.
- Martinez-Azorin F, Remacha M, Ballesta JP. 2008. Functional characterization of ribosomal P1/P2 proteins in human cells. *Biochemical Journal* 413:527–534 DOI 10.1042/bj20080049.
- Maya-López M, Rubio-López LC, Rodríguez-Alvarez IV, Orduño Piceno J, Flores-Valdivia Y, Colonnello A, Rangel-López E, Túnez I, Prospéro-García O, Santamaría A. 2020. A cannabinoid receptor-mediated mechanism participates in the neuroprotective effects of oleamide against excitotoxic damage in rat brain synaptosomes and cortical slices. *Neurotoxicity Research* 37:126–135 DOI 10.1007/s12640-019-00083-1.
- Menck K, Behme D, Pantke M, Reiling N, Binder C, Pukrop T, Klemm F. 2014. Isolation of human monocytes by double gradient centrifugation and their differentiation to macrophages in teflon-coated cell culture bags. *Journal of Visualized Experiments* 91:e51554 DOI 10.3791/51554.
- Mendelson WB, Basile AS. 2001. The hypnotic actions of the fatty acid amide, oleamide. *Neuropsychopharmacology* 25:S36–S39 DOI 10.1016/S0893-133X(01)00341-4.
- Moon J-S, Hisata S, Park M-A, De Nicola Gina M, Ryter Stefan W, Nakahira K, Choi Augustine MK. 2015. mTORC1-induced HK1-dependent glycolysis regulates NLRP3 inflammasome activation. *Cell Reports* 12:102–115 DOI 10.1016/j.celrep.2015.05.046.
- Moon SM, Lee SA, Hong JH, Kim JS, Kim DK, Kim CS. 2018. Oleamide suppresses inflammatory responses in LPS-induced RAW264.7 murine macrophages and alleviates paw edema in a carrageenan-induced inflammatory rat model. *International Immunopharmacology* **56**:179–185 DOI 10.1016/j.intimp.2018.01.032.
- Mootha VK, Lindgren CM, Eriksson K-F, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstråle M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D, Groop LC. 2003. PGC-1 α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. *Nature Genetics* 34:267–273 DOI 10.1038/ng1180.
- Nagashio R, Kuchitsu Y, Igawa S, Kusuhara S, Naoki K, Satoh Y, Ichinoe M, Murakumo Y, Saegusa M, Sato Y. 2020. Prognostic significance of NAP1L1 expression in patients with early lung adenocarcinoma. *Biomedical Research* **41**:149–159 DOI 10.2220/biomedres.**41**.149.
- Oshi M, Tokumaru Y, Asaoka M, Yan L, Satyananda V, Matsuyama R, Matsuhashi N, Futamura M, Ishikawa T, Yoshida K, Endo I, Takabe K. 2020. M1 Macrophage and M1/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer. *Scientific Reports* **10**:16554 DOI 10.1038/s41598-020-73624-w.
- Pan Y, Yu Y, Wang X, Zhang T. 2020. Tumor-associated macrophages in tumor immunity. *Frontiers in Immunology* 11:775758 DOI 10.3389/fimmu.2020.583084.

- Pe KCS, Saetung R, Yodsurang V, Chaotham C, Suppipat K, Chanvorachote P, Tawinwung S. 2022. Triple-negative breast cancer influences a mixed M1/M2 macrophage phenotype associated with tumor aggressiveness. *PLOS ONE* 17:e0273044 DOI 10.1371/journal.pone.0273044.
- Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. 2004. UCSF chimera—a visualization system for exploratory research and analysis. *Journal of Computational Chemistry* 25:1605–1612 DOI 10.1002/jcc.20084.
- **Prapakorn Wisitpongpun KU. 2022.** Anticancer effects of *Moringa oleifera* Lam. leaf extracts on the human breast cancer cells, Naresuan University.
- Queiroz CJS, Song F, Reed KR, Al-Khafaji N, Clarke AR, Vimalachandran D, Miyajima F, Pritchard DM, Jenkins JR. 2020. NAP1L1: a novel human colorectal cancer biomarker derived from animal models of Apc inactivation. *Frontiers in Oncology* 10:1565 DOI 10.3389/fonc.2020.01565.
- Ricklin D, Reis ES, Mastellos DC, Gros P, Lambris JD. 2016. Complement component C3 –the Swiss Army Knife of innate immunity and host defense. *Immunological Reviews* 274:33–58 DOI 10.1111/imr.12500.
- Ruan C-C, Ge Q, Li Y, Li X-D, Chen D-R, Ji K-D, Wu Y-J, Sheng L-J, Yan C, Zhu D-L, Gao P-J. 2015. Complement-mediated macrophage polarization in perivascular adipose tissue contributes to vascular injury in deoxycorticosterone acetate–salt mice. *Arteriosclerosis, Thrombosis, and Vascular Biology* 35:598–606 DOI 10.1161/ATVBAHA.114.304927.
- Shapovalov Maxim V, Dunbrack Roland Jr L. 2011. A smoothed backbone-dependent rotamer library for proteins derived from adaptive kernel density estimates and regressions. *Structure* 19:844–858 DOI 10.1016/j.str.2011.03.019.
- Shen B, Zhu W, Liu X, Jiang J. 2022. NAP1L1 functions as a novel prognostic biomarker associated with macrophages and promotes tumor progression by influencing the Wnt/β-catenin pathway in hepatocellular carcinoma. *Frontiers in Genetics* 13:876253 DOI 10.3389/fgene.2022.876253.
- Shi Y, Ye P, Long X. 2017. Differential expression profiles of the transcriptome in breast cancer cell lines revealed by next generation sequencing. *Cellular Physiology and Biochemistry* **44**:804–816 DOI 10.1159/000485344.
- Steen HC, Gamero AM. 2013. STAT2 phosphorylation and signaling. *JAK-STAT* 2:e25790 DOI 10.4161/jkst.25790.
- **Strzelecka A, Kwiatkowska K, Sobota A. 1997.** Tyrosine phosphorylation and Fc *γ* receptor-mediated phagocytosis. *FEBS Letters* **400**:11–14 DOI 10.1016/S0014-5793(96)01359-2.
- Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proceedings of the National Academy of Sciences of the United States of America* 102:15545–15550 DOI 10.1073/pnas.0506580102.

- Swanson KV, Deng M, Ting JPY. 2019. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. *Nature Reviews Immunology* 19:477–489 DOI 10.1038/s41577-019-0165-0.
- The Gene Ontology C, Aleksander SA, Balhoff J, Carbon S, Cherry JM, Drabkin HJ, Ebert D, Feuermann M, Gaudet P, Harris NL, Hill DP, Lee R, Mi H, Moxon S, Mungall CJ, Muruganugan A, Mushayahama T, Sternberg PW, Thomas PD, Van Auken K, Ramsey J, Siegele DA, Chisholm RL, Fey P, Aspromonte MC, Nugnes MV, Quaglia F, Tosatto S, Giglio M, Nadendla S, Antonazzo G, Attrill H, Dos Santos G, Marygold S, Strelets V, Tabone CJ, Thurmond J, Zhou P, Ahmed SH, Asanitthong P, Luna Buitrago D, Erdol MN, Gage MC, Ali Kadhum M, Li KYC, Long M, Michalak A, Pesala A, Pritazahra A, Saverimuttu SCC, Su R, Thurlow KE, Lovering RC, Logie C, Oliferenko S, Blake J, Christie K, Corbani L, Dolan ME, Drabkin HJ, Hill DP, Ni L, Sitnikov D, Smith C, Cuzick A, Seager J, Cooper L, Elser J, Jaiswal P, Gupta P, Jaiswal P, Naithani S, Lera-Ramirez M, Rutherford K, Wood V, De Pons JL, Dwinell MR, Hayman GT, Kaldunski ML, Kwitek AE, Laulederkind SJF, Tutaj MA, Vedi M, Wang S-J, D'Eustachio P, Aimo L, Axelsen K, Bridge A, Hyka-Nouspikel N, Morgat A, Aleksander SA, Cherry JM, Engel SR, Karra K, Miyasato SR, Nash RS, Skrzypek MS, Weng S, Wong ED, Bakker E, Berardini TZ, Reiser L, Auchincloss A, Axelsen K, Argoud-Puy G, Blatter M-C, Boutet E, Breuza L, Bridge A, Casals-Casas C, Coudert E, Estreicher A, Livia Famiglietti M, Feuermann M, Gos A, Gruaz-Gumowski N, Hulo C, Hyka-Nouspikel N, Jungo F, Le Mercier P, Lieberherr D, Masson P, Morgat A, Pedruzzi I, Pourcel L, Poux S, Rivoire C, Sundaram S, Bateman A, Bowler-Barnett E, Bye-A-Jee H, Denny P, Ignatchenko A, Ishtiaq R, Lock A, Lussi Y, Magrane M, Martin MJ, Orchard S, Raposo P, Speretta E, Tyagi N, Warner K, Zaru R, Diehl AD, Lee R, Chan J, Diamantakis S, Raciti D, Zarowiecki M, Fisher M, James-Zorn C, Ponferrada V, Zorn A, Ramachandran S, Ruzicka L, Westerfield M. 2023. The Gene Ontology knowledgebase in 2023. Genetics 224:iyad031 DOI 10.1093/genetics/iyad031.
- Trott O, Olson AJ. 2010. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *Journal of Computational Chemistry* 31:455–461 DOI 10.1002/jcc.21334.
- **Tugal D, Liao X, Jain MK. 2013.** Transcriptional control of macrophage polarization. *Arteriosclerosis, Thrombosis, and Vascular Biology* **33**:1135–1144 DOI 10.1161/ATVBAHA.113.301453.
- van Riggelen J, Yetil A, Felsher DW. 2010. MYC as a regulator of ribosome biogenesis and protein synthesis. *Nature Reviews Cancer* 10:301–309 DOI 10.1038/nrc2819.
- **Verdon B, Zheng J, Nicholson RA, Ganelli CR, Lees G. 2000.** Stereoselective modulatory actions of oleamide on GABA(A) receptors and voltage-gated Na(+) channels in vitro: a putative endogenous ligand for depressant drug sites in CNS. *British Journal of Pharmacology* **129**:283–290 DOI 10.1038/sj.bjp.0703051.
- Wang P, Qian H, Xiao M, Lv J. 2023. Role of signal transduction pathways in IL-1  $\beta$ induced apoptosis: pathological and therapeutic aspects. *Immunity, Inflammation and Disease* **11**:e762 DOI 10.1002/iid3.762.

- Wang T, Liu H, Lian G, Zhang S-Y, Wang X, Jiang C. 2017. HIF-1 α-induced glycolysis metabolism is essential to the activation of inflammatory macrophages. *Mediators of Inflammation* 2017:9029327 DOI 10.1155/2017/9029327.
- Wang Y, Sui J, Li X, Cao F, He J, Yang B, Zhu X, Sun Y, Pu YD. 2015. RPS24 knockdown inhibits colorectal cancer cell migration and proliferation in vitro. *Gene* 571:286–291 DOI 10.1016/j.gene.2015.06.084.
- Weidemann A, Johnson RS. 2008. Biology of HIF-1 α. Cell Death & Differentiation 15:621–627 DOI 10.1038/cdd.2008.12.
- Wisitpongpun P, Potup P, Usuwanthim K. 2022. Oleamide-mediated polarization of M1 macrophages and IL-1 β production by regulating NLRP3-inflammasome activation in primary human monocyte-derived macrophages. *Frontiers in Immunology* 13:856296 DOI 10.3389/fimmu.2022.856296.
- Wisitpongpun P, Suphrom N, Potup P, Nuengchamnong N, Calder PC, Usuwanthim
   K. 2020. In vitro bioassay-guided identification of anticancer properties from
   Moringa oleifera Lam. Leaf against the MDA-MB-231 cell line. *Pharmaceuticals* 13:464 DOI 10.3390/ph13120464.
- Woods PS, Kimmig LM, Sun KA, Meliton AY, Shamaa OR, Tian Y, Cetin-Atalay R, Sharp WW, Hamanaka RB, Mutlu GM. 2022. HIF-1 α induces glycolytic reprograming in tissue-resident alveolar macrophages to promote cell survival during acute lung injury. *eLife* 11:e77457 DOI 10.7554/eLife.77457.
- Xia Y, Li Y, Wu X, Zhang Q, Chen S, Ma X, Yu M. 2021. Ironing out the details: how iron orchestrates macrophage polarization. *Frontiers in Immunology* 12:669566.
- Xiao L, Wang Q, Peng H. 2023. Tumor-associated macrophages: new insights on their metabolic regulation and their influence in cancer immunotherapy. *Frontiers in Immunology* 14:1157291 DOI 10.3389/fimmu.2023.1157291.
- Xie Z, Bailey A, Kuleshov MV, Clarke DJB, Evangelista JE, Jenkins SL, Lachmann A, Wojciechowicz ML, Kropiwnicki E, Jagodnik KM, Jeon M, Ma'ayan A. 2021. Gene set knowledge discovery with enrichr. *Current Protocols* 1:e90 DOI 10.1002/cpz1.90.
- Yang Y, Ye Y-C, Chen Y, Zhao J-L, Gao C-C, Han H, Liu W-C, Qin H-Y. 2018. Crosstalk between hepatic tumor cells and macrophages via Wnt/β-catenin signaling promotes M2-like macrophage polarization and reinforces tumor malignant behaviors. *Cell Death* & Disease 9:793 DOI 10.1038/s41419-018-0818-0.
- Zhang M, He Y, Sun J, Li Q, Wang W, Zhao A, Di W. 2014. A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients. *Journal of Ovarian Research* 7:19 DOI 10.1186/1757-2215-7-19.
- Zheng X, Turkowski K, Mora J, Brüne B, Seeger W, Weigert A, Savai R. 2017. Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy. *Oncotarget* 8:48436–48452 DOI 10.18632/oncotarget.17061.
- Zhou J, Tang Z, Gao S, Li C, Feng Y, Zhou X. 2020. Tumor-associated macrophages: recent insights and therapies. *Frontiers in Oncology* 10:188 DOI 10.3389/fonc.2020.00188.

Zottel A, Jovčevska I, Šamec N, Mlakar J, Šribar J, Križaj I, Skoblar Vidmar M, Komel R. 2020. Anti-vimentin, anti-TUFM, anti-NAP1L1 and anti-DPYSL2 nanobodies display cytotoxic effect and reduce glioblastoma cell migration. *Therapeutic Advances in Medical Oncology* **12**:1758835920915302 DOI 10.1177/1758835920915302.